HealthLynked (HLYK) 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 14, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	HealthLynked Corp
Entity Central Index Key	1,680,139
Trading Symbol	HLYK
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		72,167,469

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current Assets
Cash	$ 16,175	$ 58,716
Accounts receivable, net	118,581	146,874
Prepaid expenses	23,712	43,545
Deferred offering costs	134,422
Total Current Assets	292,890	249,135
Property, plant and equipment, net of accumulated depreciation of $722,407 and $704,785 as of September 30, 2017 and December 31, 2016, respectively	66,452	70,836
Deposits	9,540	9,540
Total Assets	368,882	329,511
Current Liabilities
Accounts payable and accrued expenses	287,086	148,474
Capital lease, current portion	18,348	18,348
Due to related party, current portion	620,611	311,792
Notes payable, net of original issue discount and debt discount of $19,226 and $-0- as of September 30, 2017 and December 31, 2016, respectively	50,352
Convertible notes payable, net of original issue discount and debt discount of $157,612 and $114,332 as of September 30, 2017 and December 31, 2016, respectively	696,388	485,668
Derivative financial instruments	156,412
Total Current Liabilities	1,829,197	964,282
Long-Term Liabilities
Capital leases, long-term portion	25,993	39,754
Due to related party, long-term portion	253,242	237,157
Total Liabilities	2,108,432	1,241,193
Shareholders' Deficit
Common stock, par value $0.0001 per share, 230,000,000 shares authorized, 70,676,254 and 65,753,640 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	7,068	6,575
Common stock issuable, $0.0001 par value; 10,313 and 80,643 shares as of September 30, 2017 and December 31, 2016, respectively	3,124	6,451
Additional paid-in capital	2,333,224	1,199,511
Accumulated deficit	(4,082,966)	(2,124,219)
Total Shareholders' Deficit	(1,739,550)	(911,682)
Total Liabilities and Shareholders' Deficit	$ 368,882	$ 329,511

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Property, plant and equipment, net of accumulated depreciation	$ 722,407	$ 704,785
Original issue discount	19,226	0
Convertible notes payable, net of original issue discount and debt discount	$ 157,612	$ 114,332
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	230,000,000	230,000,000
Common stock, shares issued	70,676,254	65,753,640
Common stock, shares outstanding	70,676,254	65,753,640
Common stock issuable, par value	$ 0.0001	$ 0.0001
Common stock issuable, shares	10,313	80,643

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue
Patient service revenue, net	$ 480,723	$ 499,448	$ 1,473,639	$ 1,515,293
Operating Expenses
Salaries and benefits	506,206	432,949	1,469,211	1,134,073
General and administrative	480,614	513,404	1,369,018	1,148,564
Depreciation and amortization	6,056	5,718	17,623	15,804
Total Operating Expenses	992,876	952,071	2,855,852	2,298,441
(Loss) income from operations	(512,153)	(452,623)	(1,382,213)	(783,148)
Other Income (Expenses)
Loss on extinguishment of debt	(290,581)		(290,581)
Financing cost	(32,324)		(32,324)
Amortization of original issue and debt discounts on notes payable and convertible notes	(63,552)	(100,187)	(194,120)	(100,187)
Proceeds from settlement of lawsuit		38,236		38,236
Change in fair value of derivative financial instrument	5,412		5,412
Interest expense	(27,124)	(13,409)	(64,921)	(24,391)
Total other expenses	(408,169)	(75,360)	(576,534)	(86,342)
Net loss before provision for income taxes	(920,322)	(527,983)	(1,958,747)	(869,490)
Provision for income taxes
Net loss	$ (920,322)	$ (527,983)	$ (1,958,747)	$ (869,490)
Net loss per share, basic and diluted:
Basic	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.01)
Fully diluted	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.01)
Weighted average number of common shares:
Basic	69,625,763	64,215,769	68,805,330	61,984,252
Fully diluted	69,625,763	64,215,769	68,805,330	61,984,252

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Shareholders' Deficit (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($)	Total	Common Stock	Common Stock Issuable	Additional Paid-in Capital	Accumulated Deficit
Balance at Dec. 31, 2016	$ (911,682)	$ 6,575	$ 6,451	$ 1,199,511	$ (2,124,219)
Balance, Shares at Dec. 31, 2016		65,753,640
Sale of common stock	$ 548,356	$ 448		$ 547,908
Sale of common stock, Shares		4,469,514
Fair value of warrants allocated to proceeds of convertible notes payable	73,696			73,696
Fair value of warrants issued pursuant to Amended Investment Agreement	153,625			153,625
Fair value of warrants issued to extend convertible notes payable	290,581			290,581
Consultant fees payable with common shares and warrants	48,784	$ 28	(3,327)	52,083
Consultant fees payable with common shares and warrants, Shares		276,850
Shares and options issued pursuant to employee equity incentive plan	15,837	$ 17		15,820
Shares and options issued pursuant to employee equity incentive plan, Shares		176,250
Net loss	(1,958,747)				(1,958,747)
Balance at Sep. 30, 2017	$ (1,739,550)	$ 7,068	$ 3,124	$ 2,333,224	$ (4,082,966)
Balance, Shares at Sep. 30, 2017		70,676,254

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash Flows from Operating Activities
Net loss	$ (1,958,747)	$ (869,490)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation	17,623	15,804
Stock based compensation, including amortization of prepaid fees	83,823	120,037
Amortization of original issue discount and debt discount on convertible notes	194,120	100,187
Financing cost	32,324
Change in fair value of derivative financial instrument	(5,412)
Loss on extinguishment of debt	290,581
Non-cash expenses		75,000
Changes in operating assets and liabilities:
Accounts receivable	28,293	107,607
Prepaid expenses and deposits	19,832	36,261
Accounts payable and accrued expenses	138,613	(93,834)
Due to related party, current portion	27,627	11,986
Net cash used in operating activities	(1,131,324)	(496,441)
Cash Flows from Investing Activities
Acquisition of property and equipment	(13,238)	(12,611)
Net cash used in investing activities	(13,238)	(12,611)
Cash Flows from Financing Activities
Proceeds from sale of common stock	548,356	374,000
Proceeds from issuance of convertible notes	229,500	475,000
Proceeds from related party loans	308,470	176,500
Repayment of related party loans	(11,192)	(123,273)
Proceeds from issuance of notes payable	75,010
Repayment of notes payable and bank loans	(34,362)	(84,980)
Payments on capital leases	(13,761)	(13,761)
Net cash provided by financing activities	1,102,021	803,486
Net increase (decrease) in cash	(42,541)	294,434
Cash, beginning of period	58,716	29,779
Cash, end of period	16,175
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	1,002	3,438
Cash paid during the period for income tax
Schedule of non-cash investing and financing activities:
Fair value of warrants issued to extend maturity date of convertible notes payable, recognized as discount against convertible notes payable	7,506
Fair value of warrants issued pursuant to Amended Investment Agreement	153,625
Fair value of warrants, beneficial conversion feature and original issue discount allocated to proceeds of convertible notes payable	66,190	272,957
Initial derivative liabilities, beneficial conversion features and original issue discounts allocated to proceeds of convertible notes payable	153,625
Common stock issuable issued during period	6,451	45,000
Common stock issued for preferred stock conversion		$ 295

Business and Business Presentat

Business and Business Presentation	9 Months Ended
	Sep. 30, 2017
Business and Business Presentation [Abstract]
BUSINESS AND BUSINESS PRESENTATION	NOTE 1 - BUSINESS AND BUSINESS PRESENTATION HealthLynked Corporation, a Nevada corporation (the “Company” or “HLYK”) filed its Articles of Incorporation on August 4, 2014. On September 3, 2014 HLYK filed Amended Articles of Incorporation clarifying that the total authorized shares of 250,000,000 shares are broken up between 230,000,000 common shares and 20,000,000 preferred shares. On September 5, 2014, HLYK entered into a share exchange agreement (the “Share Exchange Agreement”) with Naples Women’s Center LLC (“NWC”), a Florida Limited Liability Company (“LLC”), acquiring 100% of the LLC membership units of NWC through the issuance of 50,000,000 shares of HLYK common stock to the members of NWC (the “Restructuring”). NWC is a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice located in Naples, Florida. HLYK operates an online personal medical information and record archive system, the “HealthLynked Network”, which enables patients and doctors to keep track of medical information via the Internet in a cloud based system. Patients complete a detailed online personal medical history including past surgical history, medications, allergies, and family history. Once this information is entered patients and their treating physicians are able to update the information as needed to provide a comprehensive medical history. These unaudited condensed consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended December 31, 2016 and 2015, respectively, which are included in Amendment #2 to the Company’s Registration Statement on Form S-1 filed with the United States Securities and Exchange Commission on March 23, 2017. The Company assumes that the users of the interim financial information herein have read, or have access to, the audited consolidated financial statements for the preceding period, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context. The results of operations for the three and nine months ended September 30, 2017 are not necessarily indicative of results for the entire year ending December 31, 2017. All significant intercompany transactions and balances have been eliminated upon consolidation. In addition, certain amounts in the prior periods’ consolidated financial statements have been reclassified to conform to the current period presentation.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying condensed consolidated financial statements follows: Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets and useful life of fixed assets. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Patient service revenues are recognized at the time of service for the net amount expected to be collected. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments Cash and Cash Equivalents For financial statement purposes, the Company considers all highly-liquid investments with original maturities of three months or less to be cash and cash equivalents. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 45% of total billings. Trade accounts receivable are recorded at this net amount. As of September 30, 2017 and December 31, 2016, the Company’s gross accounts receivable were $269,501 and $333,804, respectively, and net accounts receivable were $118,581 and $146,874, respectively, based upon net reporting of accounts receivable. Capital Leases Costs associated with capitalized leases are capitalized and depreciated ratably over the term of the related useful life of the asset and/or the capital lease term. The related depreciation for the three months ended September 30, 2017 and 2016 was $4,587 and $4,587, respectively. The related depreciation for the nine months ended September 30, 2017 and 2016 was $13,761 and $13,761, respectively. Accumulated depreciation of capitalized leases was $299,151 and $285,390 at September 30, 2017 and December 31, 2016, respectively. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. There was no impairment as of September 30, 2017 and December 31, 2016. Convertible Notes Convertible notes are regarded as compound instruments, consisting of a liability component and an equity component. The component parts of compound instruments are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortized cost basis until extinguished upon conversion or at the instrument’s maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized as additional paid-in capital and included in equity, net of income tax effects, and is not subsequently remeasured. After initial measurement, they are carried at amortized cost using the effective interest method. Derivative Financial Instruments The Company reviews the terms of convertible debt, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received, an immediate charge to income is recognized, in order to initially record the derivative instrument liabilities at their fair value. The discount from the face value of convertible debt instruments resulting from allocating some or all of the proceeds to the derivative instruments is amortized over the life of the instrument through periodic charges to income. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – ● Level 2 ● Level 3 The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs. Stock-Based Compensation The Company accounts for stock based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, short-term borrowings, accounts payable, accrued liabilities, and derivative financial instruments approximated their fair value. Net Income (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three and nine month periods ended September 30, 2017 and 2016, the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of September 30, 2017 and 2016, potentially dilutive securities were comprised of (i) 19,566,389 and 10,576,389 warrants outstanding, respectively, (ii) 2,349,996 and 1,600,000 stock options outstanding, respectively, (iii) 8,675,180 and 7,375,000 shares issuable upon conversion of convertible notes, respectively, and (iv) 528,750 and 940,000 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan. Recent Accounting Pronouncements In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842). The effective date for ASU 2017-13 is for fiscal years beginning after December 15, 2018. We are currently evaluating the impact of adopting ASU 2017-13 on our unaudited consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350), which simplifies the goodwill impairment test. The effective date for ASU 2017-04 is for fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact of adopting ASU 2017-04 on our unaudited condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted with prospective application to any business development transaction. We are currently evaluating the impact of adopting ASU 2017-04 on our unaudited condensed consolidated financial statements. The Company applied ASU 2015-03: Interest – Imputation of Interest, which simplifies the presentation of debt issuance costs, and netted debt issue costs previously reported as assets with the related liability for presentation purposes. On May 28, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. The standard will eliminate the transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. The Company intends to adopt this guidance for the year ended December 31, 2017. The Company has not yet evaluated the impact the adoption this standard will have on its results of operations upon adoption. In August 2014, the FASB issued ASU No. 2014-15 Presentation of Financial Statements-Going Concern. The amendments in this update apply to all reporting entities and require an entity’s management, in connection with preparing financial statements for each annual and interim reporting period, to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). This ASU is effective for annual periods ending after December 15, 2016. The Company adopted this standard for the year ended December 31, 2016. Based on the results of our analysis, no additional disclosures were required. The Company has evaluated recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC and we have not identified any that would have a material impact on the Company’s financial position, or statements.

Going Concern Matters and Liqui

Going Concern Matters and Liquidity	9 Months Ended
	Sep. 30, 2017
Going Concern Matters and Liquidity [Abstract]
GOING CONCERN MATTERS AND LIQUIDITY	NOTE 3 – GOING CONCERN MATTERS AND LIQUIDITY As of September 30, 2017, the Company had a working capital deficit of $1,536,307 and accumulated deficit $4,082,966. For the nine months ended September 30, 2017, the Company had a net loss of $1,958,747 and net cash used by operating activities of $1,131,324. Net cash used in investing activities was $13,238. Net cash provided by financing activities was $1,102,021, resulting principally from $548,356 from the proceeds of the sale of 4,469,514 shares of common stock, $308,470 proceeds from related party loans and $229,500 net proceeds from the issuance of convertible notes. Subsequent to September 30, 2017, the Company received additional $150,000 net proceeds from the sale of a convertible promissory note and $200,000 from the sale of 1,000,000 common shares with an attached five-year warrant to purchase 666,666 shares of the Company’s common stock at an exercise price of $0.30 per share (see Note 14). The Company’s cash balance and revenues generated are not currently sufficient and cannot be projected to cover its operating expenses for the next twelve months from the date of this report. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include attempting to improve its business profitability and its ability to generate sufficient cash flow from its operations to meet its needs on a timely basis, obtaining additional working capital funds through equity and debt financing arrangements, and restructuring on-going operations to eliminate inefficiencies to raise cash balance in order to meet its anticipated cash requirements for the next twelve months from the date of this report. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures, working capital, and other requirements. Management intends to make every effort to identify and develop sources of funds. The outcome of these matters cannot be predicted at this time. There can be no assurance that any additional financings will be available to the Company on satisfactory terms and conditions, if at all. The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. During the year ended December 31, 2016, HLYK (i) received proceeds of $374,000 from the sale of 6,167,500 shares of common stock, (ii) received net proceeds of $475,000 from the issuance of convertible promissory notes with a combined face value of $600,000, and (iii) entered into an Investment Agreement (the “Investment Agreement”) pursuant to which the investor has agreed to purchase up to $3,000,000 of HLYK common stock over a three-year period starting upon registration of the underlying shares, with such shares put to the investor by the Company pursuant to a specified formula that limits the number of shares able to be put to the investor to the number equal to the average trading volume of the Company’s common shares for the ten consecutive trading days prior to the put notice being issued. During the nine months ended September 30, 2017, the Company received $15,356 from the proceeds of the sale of 57,016 shares pursuant to the Investment Agreement. The Company intends that the cost of implementing its development and sales efforts related to the HealthLynked Network, as well as maintaining its existing and expanding overhead and administrative costs, will be funded principally by cash received by the Company from the put rights associated with the Investment Agreement and supplemented by other funding mechanisms, including loans from related parties and convertible notes. The Company expects to repay its outstanding convertible notes – of which $111,000 face value matures on January 22, 2018, $53,000 on April 15, 2018, $35,000 on June 15, 2018, $550,000 on July 7, 2018, and $50,000 on July 11, 2018, and $55,000 on September 11, 2018 – from outside funding sources, including but not limited to amounts available upon the exercise of the put rights granted to the Company under the Investment Agreement, sales of equity, loans from related parties and others or through the conversion of the notes into equity. No assurances can be given that the Company will be able to access sufficient outside capital in a timely fashion in order to repay the convertible notes before they mature. If necessary funds are not available, the Company’s business and operations would be materially adversely affected and in such event, the Company would attempt to reduce costs and adjust its business plan.

Deferred Offering Costs

Deferred Offering Costs	9 Months Ended
	Sep. 30, 2017
Deferred Offering Costs [Abstract]
DEFERRED OFFERING COSTS	NOTE 4 – DEFERRED OFFERING COSTS On July 7, 2016, the Company entered into the Investment Agreement with an accredited investor, pursuant to which an accredited investor agreed to invest up to $3,000,000 to purchase the Company’s common stock, par value of $.0001 per share. The purchase price for such shares shall be 80% of the lowest volume weighted average price of the Company’s common stock during the five consecutive trading days prior to the date on which written notice is sent by the Company to the investor stating the number of shares that the Company is selling to the investor, subject to certain discounts and adjustments. Further, for each $50,000 that the investor tenders to the Company for the purchase of shares of common stock, the investor was to be granted warrants for the purchase of an equivalent number of shares of common stock. The warrants were to expire five (5) years from their respective grant dates and have an exercise price equal to 130% of the weighted average purchase price for the respective “$50,000 increment.” On March 22, 2017, the Company and the investor entered into an Amended Investment Agreement (the “Amended Investment Agreement”) whereby the parties agreed to modify the terms of the Investment Agreement by providing that in lieu of granting the investor warrants for each $50,000 that the investor tenders to the Company, the Company granted to the investor warrants to purchase an aggregate of 7,000,000 shares of common stock. The warrants have the following fixed exercise prices: (i) 4,000,000 shares at $0.25 per share; (ii) 2,000,000 shares at $0.50 per share; and (iii) 1,000,000 shares at $1.00 per share. The warrants also contain a “cashless exercise” provision and the shares underlying the warrants will not be registered. The fair value of the warrants was calculated using the Black-Scholes pricing model at $56,635, with the following assumptions: risk-free interest rate of 1.95%, expected life of 5 years, volatility of 40%, and expected dividend yield of zero. On June 7, 2017, the Company also granted warrants to purchase 200,000 shares at $0.25 per share, 100,000 shares at $0.50 per share and 50,000 shares at $1.00 per share to an advisor as a fee in connection with the Amended Investment Agreement. The fair value of the warrants was calculated using the Black-Scholes pricing model at $96,990, with the following assumptions: risk-free interest rate of 1.74%, expected life of 5 years, volatility of 40%, and expected dividend yield of zero. This fair value of the warrants was recorded as a deferred offering cost and will be amortized over the period during which the Company can access the financing, which begins the day after a registration statement registering shares underlying the Investment Agreement is declared effective by the United States Securities and Exchange Commission (the “SEC”), and ends 3 years from that date. On May 15, 2017, the SEC declared effective a registration statement registering shares underlying the Investment Agreement. During the three and nine months ended September 30, 2017, the Company recognized $12,802 and $19,203, respectively, in general and administrative expense related to the cost of the warrants.

Property, Plant, and Equipment

Property, Plant, and Equipment	9 Months Ended
	Sep. 30, 2017
Property, Plant, and Equipment [Abstract]
PROPERTY, PLANT, AND EQUIPMENT	NOTE 5 – PROPERTY, PLANT, AND EQUIPMENT Property, plant and equipment at September 30, 2017 and December 31, 2016 are as follows: September 30, December 31, 2017 2016 (audited) Capital Lease equipment $ 343,492 $ 343,492 Telephone equipment 12,308 12,308 Furniture, Transport and Office equipment 433,059 419,821 Total Property, plant and equipment 788,859 775,621 Less: accumulated depreciation (722,407 ) (704,785 ) Property, plant and equipment, net $ 66,452 $ 70,836 Depreciation expense during the three months ended September 30, 2017 and 2016 was $6,055 and $5,718, respectively. Depreciation expense during the nine months ended September 30, 2017 and 2016 was $17,622 and $15,804, respectively.

Due to Related Party

Due to Related Party	9 Months Ended
	Sep. 30, 2017
Due to Related Party [Abstract]
DUE TO RELATED PARTY	NOTE 6 – DUE TO RELATED PARTY Amounts due to related parties as of September 30, 2017 and December 31, 2016 were comprised of the following: September 30, December 31, 2017 2016 (audited) Current portion: Notes payable and accrued interest, Dr. Michael Dent $ 320,011 $ --- Deferred compensation, Dr. Michael Dent 300,600 300,600 Due to MedOffice Direct --- 11,192 Total current portion 620,611 311,792 Long term portion: Notes payable and accrued interest, Dr. Michael Dent 253,242 237,157 Total due to related parties $ 873,853 $ 548,949 Dr. Michael Dent Prior to August 2014, NWC was owned and controlled by the Company’s Chief Executive Officer, Dr. Michael Dent (“DMD”). DMD first provided an up to $175,000 unsecured note payable to the Company with a 0% interest rate. During 2013 the limit on the unsecured Note Payable was increased up to $500,000 and during 2014 it was increased to $750,000 with a maturity date of December 31, 2017. During January 2017, the note was again amended to extend the maturity date until December 31, 2018, to accrue interest on outstanding balances after January 1, 2017 at a rate of 10% per annum, and to fix interest accrued on balances between January 1, 2015 and December 31, 2016 at an amount equal to $22,108 (the “$750k DMD Note”). All principal and interest is due at maturity of the $750k DMD Note. Interest accrued on the $750k DMD Note as of September 30, 2017 and December 31, 2016 was $38,192 and $22,108, respectively. During the nine months ended September 30, 2017, the Company borrowed $308,500 from Dr. Dent under unsecured promissory notes as follows: Inception Date Maturity Date Interest Rate Amount January 12, 2017 January 13, 2018 10 % $ 35,000 January 18, 2017 January 19, 2018 10 % 20,000 January 24, 2017 January 15, 2018 10 % 50,000 February 9, 2017 February 10, 2018 10 % 30,000 April 20, 2017 April 21, 2018 15 % 10,000 June 15, 2017 June 16, 2018 10 % 32,500 August 17, 2017 August 18, 2018 10 % 20,000 August 24, 2017 August 25, 2018 10 % 37,500 September 7, 2017 September 8, 2018 10 % 35,000 September 21, 2017 September 22, 2018 10 % 26,500 September 29, 2017 September 30, 2018 10 % 12,000 $ 308,500 Interest accrued on the 2017 DMD Notes as of September 30, 2017 and December 31, 2016 was $11,511 and -0-, respectively. MedOffice Direct During 2016, MedOffice Direct (“MOD”), a company majority-owned by the Company’s CEO and largest shareholder, Dr. Michael Dent, paid a direct obligation of the Company in the amount of $25,000. The Company also paid direct obligations of MOD totaling $13,808 in 2016, resulting in an amount payable to MOD of $11,192 as of December 31, 2016. This amount was paid in full in January 2017. During the nine months ended September 30, 2017, the Company entered into an agreement with MOD pursuant to which the Company will pay rent to MOD in the amount of $2,040 per month for office space in MOD’s facility used by the Company and its employees. The agreement is effective from January 1, 2017 through July 31, 2018. During the three and nine months ended September 30, 2017, the Company recognized rent expense related to the marketing agreement in the amount of $6,120 and $18,360, respectively, pursuant to this agreement and had prepaid an additional $4,929 toward future rent as of September 30, 2017.

Capital Lease

Capital Lease	9 Months Ended
	Sep. 30, 2017
Capital Lease/Notes Payable/Convertible Notes Payable [Abstract]
CAPITAL LEASE	NOTE 7 – CAPITAL LEASE Capital lease obligations as of September 30, 2017 and December 31, 2016 are comprised of the following: September 30, December 31, 2017 2016 (audited) Note payable, New Everbank Lease $ 44,341 $ 58,102 Less: note payable, New Everbank Lease (Capital leases), current portion (18,348 ) (18,348 ) Notes payable, bank loans and capital leases, long-term portion $ 25,993 $ 39,754 In March 2015, the Company entered into a capital equipment finance lease for Ultra Sound equipment with Everbank. There was no interest on this lease. The monthly payment is $1,529 for 60 months ending in March 2020. As of September 30, 2017, the Company owed Everbank $48,928 pursuant to this capital lease. During the nine months ended September 30, 2017 and 2016, the Company made payments on capital leases of $13,761 and $13,761, respectively. Future minimum payments to which the Company is obligated pursuant to the capital leases as of September 30, 2017 are as follows: 2017 (October to December) $ 4,587 2018 18,348 2019 18,348 2020 3,058 2021 --- Total $ 44,341

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2017
Capital Lease/Notes Payable/Convertible Notes Payable [Abstract]
NOTES PAYABLE	NOTE 8 – NOTES PAYABLE On July 11, 2017, the Company entered into a Merchant Cash Advance Factoring Agreement (“MCA”) with Power Up Lending Group, Ltd. (the “PULG”) pursuant to which the Company received an advance of $26,000 before closing fees. The Company is required to repay the advance, which acts like an ordinary note payable, at the rate of $1,372 per week until the balance of $34,580 has been repaid. At inception, the Company recognized a note payable in the amount of $34,580 and a discount against the note payable of $9,550. The discount is being amortized over the life of the instrument. During each of the three and nine month periods ending September 30, 2017, the Company recognized amortization of the discount in the amount of $4,227. As of September 30, 2017, the net carrying value of the instrument was $14,162. On August 9, 2017, the Company entered into a second MCA with PULG pursuant to which the Company received an advance of $51,000 before closing fees. The Company is required to repay the advance, which acts like an ordinary note payable, at the rate of $2,752 per week until the balance of $69,360 has been repaid. At inception, the Company recognized a note payable in the amount of $69,360 and a discount against the note payable of $19,380. The discount is being amortized over the life of the instrument. During each of the three and nine month periods ending September 30, 2017, the Company recognized amortization of the discount in the amount of $5,477. As of September 30, 2017, the net carrying value of the instrument was $36,190.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2017
Capital Lease/Notes Payable/Convertible Notes Payable [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 9 –CONVERTIBLE NOTES PAYABLE Convertible notes payable as of September 30, 2017 and December 31, 2016 are comprised of the following: September 30, December 31, 2017 2016 (audited) Face Value $550k Note - July 2016 $ 550,000 $ 550,000 $50k Note - July 2016 50,000 50,000 $111k Note - May 2017 111,000 --- $53k Note - July 2017 53,000 --- $35k Note - September 2017 35,000 --- $55k Note - September 2017 55,000 --- 854,000 600,000 Unamortized Discount $550k Note - July 2016 $ --- $ (96,631 ) $50k Note - July 2016 --- (17,701 ) $111k Note - May 2017 (35,917 ) --- $53k Note - July 2017 (37,423 ) --- $35k Note - September 2017 (32,135 ) --- $55k Note - September 2017 (52,137 ) --- (157,612 ) (114,332 ) Net Book Value $550k Note - July 2016 $ 550,000 $ 453,369 $50k Note - July 2016 50,000 32,299 $111k Note - May 2017 75,083 --- $53k Note - July 2017 15,577 --- $35k Note - September 2017 2,865 --- $55k Note - September 2017 2,863 --- Convertible notes payable, net of original issue discount and debt discount $ 696,388 $ 485,668 Convertible Notes Payable ($550,000) – July 2016 On July 7, 2016, the Company entered into a 6% fixed convertible secured promissory note with an investor with a face value of $550,000 (the “$550k Note”). The $550k Note is convertible into shares of the Company’s common stock at the discretion of the note holder at a fixed price of $0.08 per share, and is secured by all of the Company’s assets. The Company received $500,000 net proceeds from the note after a $50,000 original issue discount. At inception, the investors were also granted a five-year warrant to purchase 6,111,111 shares of the Company’s common stock at an exercise price of $0.09 per share. The fair value of the warrants was calculated using the Black-Scholes pricing model at $157,812, with the following assumptions: risk-free interest rate of 0.97%, expected life of 5 years, volatility of 40%, and expected dividend yield of zero. The net proceeds from the issuance of the $550k Note, being $500,000 after the original issue discount, were then allocated to the warrants and the convertible note instrument based on their relative fair values, of which $111,479 was allocated to the warrants and $388,521 to the convertible note. The intrinsic value of the embedded conversion feature of the $550k Note was then calculated as $161,479. The original issue discount, warrants and embedded conversion feature were then allocated and recorded as discounts against the carrying value of the $550k Note. The final allocation of the proceeds at inception was as follows: Original issue discount $ 50,000 Warrants 111,479 Embedded conversion feature 161,479 Convertible note 227,042 Face value of convertible note $ 550,000 The $550k Note was originally schedule to mature on April 11, 2017. During February 2017, the holder of the $550k Note agreed to extend the maturity date until July 7, 2017 in exchange for a five-year warrant to purchase 500,000 shares of HLYK common stock at an exercise price of $0.15 per share. The fair value of the warrants of $7,506 was recorded as an additional discount against the $550k Note and was amortized over the new remaining life of the $550k Note. The fair value of the warrant was calculated using the Black-Scholes pricing model at $7,506, with the following assumptions: risk-free interest rate of 1.89%, expected life of 5 years, volatility of 40%, and expected dividend yield of zero. The issuance of the warrants in exchange for the maturity extension was treated as a modification of existing debt pursuant to the guidance of ASC 470-50 “Debt – Modifications and Extinguishments” (“ASC 470-50”). On August 8, 2017, in exchange for a five-year warrant to purchase 1,000,000 shares of HLYK common stock at an exercise price of $0.30 per share, the holder of the $550k Note agreed to (i) further extend the maturity date of the $550k Note until July 7, 2018, and (ii) further extend the maturity date of the $50k Note (as defined herein) until July 11, 2018. The fair value of the warrant was calculated using the Black-Scholes pricing model at $290,581, with the following assumptions: risk-free interest rate of 1.81%, expected life of 5 years, volatility of 190.86%, and expected dividend yield of zero. The issuance of the warrants in exchange for the maturity extension was treated as a modification of existing debt pursuant to the guidance of ASC 470-50. Because the fair value of the warrants was greater than 10% of the present value of the remaining cash flows under the $550k Note and $50k Note, the transaction was treated as a debt extinguishment and reissuance of a new debt instrument, with the fair value of the warrants of $290,581 recorded as a loss on debt extinguishment. The carrying value of the $550k Note (as well as the $50k Note) did not change as a result of the extinguishment since the discounts recognized at inception of both notes were fully amortized at the time of the warrant issuance. The discounts resulting from the original issue discount, warrants and embedded conversion feature were amortized over the life of the $550k Note. Amortization expense related to these discounts in the three months ended September 30, 2017 and 2016 was $3,061 and $100,187, respectively. Amortization expense related to these discounts in the nine months ended September 30, 2017 and 2016 was $104,137 and $100,187, respectively. As of September 30, 2017, the unamortized discount was $-0-. As of September 30, 2017, the $550k note was convertible into 6,875,000 of the Company’s common shares. During the nine months ended September 30, 2017 and 2016, the Company made no repayments on the $550k Note. During the three months ended September 30, 2017 and 2016, the Company recorded interest expense on the $550k Note totaling $8,318 and $7,685, respectively. During the nine months ended September 30, 2017 and 2016, the Company recorded interest expense on the $550k Note totaling $24,682 and $7,685, respectively. Convertible Notes Payable ($50,000) – July 2016 On July 7, 2016, the Company entered into a 10% fixed convertible commitment fee promissory note with an investor with a face value of $50,000 maturing on July 11, 2017 (the “$50k Note”). The $50k note was issued as a commitment fee payable to the Investment Agreement investor in exchange for the investor’s commitment to enter into the Investment Agreement, subject to registration of the shares underlying the Investment Agreement. The $50k Note is convertible into shares of the Company’s common stock at the discretion of the note holder at a fixed price of $0.10 per share. The embedded conversion feature did not have any intrinsic value at issuance. Accordingly, the full face value of $50,000 was allocated to the convertible note instrument. As of September 30, 2017, the $50k Note was convertible into 500,000 of the Company’s common shares. During the nine months ended September 30, 2017 and 2016, the Company made no repayments on the $50k Note. During the three months ended September 30, 2017 and 2016, the Company recorded interest expense on the $50k Note totaling $1,260 and $1,164, respectively. During the nine months ended September 30, 2017 and 2016, the Company recorded interest expense on the $50k Note totaling $3,740 and $1,164, respectively. Convertible Notes Payable ($111,000) – May 2017 On May 22, 2017, the Company entered into a 10% fixed convertible secured promissory note with an investor with a face value of $111,000 (the “$111k Note”). The $111k Note matures on January 22, 2018. The $111k Note is convertible into shares of the Company’s common stock at the discretion of the note holder at a fixed price of $0.35 per share, and is secured by all of the Company’s assets. The Company received $100,000 net proceeds from the note after an $11,000 original issue discount. At inception, the investors were also granted a five-year warrant to purchase 133,333 shares of the Company’s common stock at an exercise price of $0.75 per share. The fair value of the warrants was calculated using the Black-Scholes pricing model at $42,305, with the following assumptions: risk-free interest rate of 1.80%, expected life of 5 years, volatility of 40%, and expected dividend yield of zero. The net proceeds from the issuance of the $111k Note, being $100,000 after the original issue discount, were then allocated to the warrants and the convertible note instrument based on their relative fair values, of which $27,595 was allocated to the warrants and $72,405 to the convertible note. The intrinsic value of the embedded conversion feature of the $111k note was then calculated as $38,595. The original issue discount, warrants and embedded conversion feature were then allocated and recorded as discounts against the carrying value of the $111k Note. The final allocation of the proceeds at inception was as follows: Original issue discount $ 11,000 Warrants 27,595 Embedded conversion feature 38,595 Convertible note 33,810 Notes payable and bank loans, long-term portion $ 111,000 The discounts resulting from the original issue discount, warrants and embedded conversion feature are being amortized over the life of the $111k Note. Amortization expense related to these discounts in the three and nine months ended September 30, 2017 was $28,986 and $41,273, respectively. No amortization expense was recognized during 2016 related to the $111k Note. As of September 30, 2017, the unamortized discount was $35,917. As of September 30, 2017, the $550k note was convertible into 317,143 of the Company’s common shares. During the nine months ended September 30, 2017 and 2016, the Company made no repayments on the $111k Note. During the three and nine months ended September 30, 2017 and 2016, the Company recorded interest expense on the $111k Note totaling $4,168 and $5,935, respectively. No interest expense was recognized on this note in 2016. Convertible Notes Payable ($53,000) – July 2017 On July 10, 2017, the Company entered into a securities purchase agreement for the sale of a $53,000 convertible note (the “$53k Note”) to PULG. The $53k Note included a $3,000 original issue discount, for net proceeds of $50,000. The $53k Note has an interest rate of 10% and a default interest rate of 22%. The $53k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the $53k Note, 150% of the outstanding principal and any interest due amount shall be immediately due. The fair value of the embedded conversion feature (“ECF”) of the $53k Note was calculated using the Black-Scholes pricing model at $58,154, with the following assumptions: risk-free interest rate of 1.23%, expected life of 0.76 years, volatility of 183.6%, and expected dividend yield of zero. Because the fair value of the ECF exceeded the net proceeds from the $53k Note, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $58,154 over the net proceeds from the note of $50,000, for a net charge of $8,154. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 58,154 Original issue discount 3,000 Financing cost (8,154 ) Convertible note --- Notes payable and bank loans, long-term portion $ 53,000 The discounts resulting from the original issue discount, warrants and embedded conversion feature are being amortized over the life of the $53k Note. Amortization expense related to these discounts in each of the three and nine months ended September 30, 2017 was $15,577. No amortization expense was recognized during 2016 related to the $53k Note. As of September 30, 2017, the unamortized discount was $37,423. As of September 30, 2017, the $53k Note was convertible into 362,022 of the Company’s common shares, based on a 39% discount to the last sale price of the Company’s common stock of $0.24 on September 30, 2017. During the nine months ended September 30, 2017 and 2016, the Company made no repayments on the $53k Note. During the three and nine months ended September 30, 2017 and 2016, the Company recorded interest expense on the $53k Note totaling $1,191 and $1,191, respectively. No interest expense was recognized on this note in 2016. Convertible Notes Payable ($35,000) – September 2017 On September 7, 2017, the Company entered into a securities purchase agreement for the sale of a $35,000 convertible note (the “$35k Note”) to PULG. The $35k Note included a $3,000 original issue discount, for net proceeds of $32,000. The $35k Note has an interest rate of 10% and a default interest rate of 20%. The $35k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the $35k Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the $35k Note, 150% of the outstanding principal and any interest due amount shall be immediately due. The fair value of the ECF of the $35k Note was calculated using the Black-Scholes pricing model at $38,338, with the following assumptions: risk-free interest rate of 1.21%, expected life of 0.77 years, volatility of 177.2%, and expected dividend yield of zero. Because the fair value of the ECF exceeded the net proceeds from the $35k Note, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $38,338 over the net proceeds from the note of $32,000, for a net charge of $6,338. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 38,338 Original issue discount 3,000 Financing cost (6,338 ) Convertible note --- Notes payable and bank loans, long-term portion $ 35,000 The discounts resulting from the original issue discount, warrants and embedded conversion feature are being amortized over the life of the $35k Note. Amortization expense related to these discounts in each of the three and nine months ended September 30, 2017 was $2,865. No amortization expense was recognized during 2016 related to the $35k Note. As of September 30, 2017, the unamortized discount was $32,135. As of September 30, 2017, the $35k Note was convertible into 239,071 of the Company’s common shares, based on a 39% discount to the last sale price of the Company’s common stock of $0.24 on September 30, 2017. During the nine months ended September 30, 2017 and 2016, the Company made no repayments on the $35k Note. During the three and nine months ended September 30, 2017 and 2016, the Company recorded interest expense on the $35k Note totaling $220 and $220, respectively. No interest expense was recognized on this note in 2016. Convertible Notes Payable ($55,000) – September 2017 On September 11, 2017, the Company entered into a securities purchase agreement for the sale of a $55,000 convertible note (the “$55k Note”) to Crown Bridge Partners LLC. The $55k Note included a $7,500 original issue discount, for net proceeds of $47,500. The 55k Note has an interest rate of 10% and a default interest rate of 12%. The $55k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 60% multiplied by the lowest one (1) trading price for the Common Stock during the twenty (20) trading day period ending on the last complete trading day prior to the date of conversion. If, at any time while the $55k Note is outstanding, the conversion price pursuant to this formula is equal to or lower than $0.10, then an additional ten percent (10%) discount shall be factored into the conversion price until the $55k Note is no longer outstanding. In the event that shares of the Company’s Common Stock are not deliverable via DWAC following the conversion of any amount hereunder, an additional ten percent (10%) discount shall be factored into the Variable Conversion Price until the Note is no longer outstanding. The fair value of the ECF of the $55k Note was calculated using the Black-Scholes pricing model at $65,332, with the following assumptions: risk-free interest rate of 1.24%, expected life of 1 year, volatility of 175.1%, and expected dividend yield of zero. Because the fair value of the ECF exceeded the net proceeds from the $55k Note, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $65,332 over the net proceeds from the note of $47,500, for a net charge of $17,832. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 65,332 Original issue discount 7,500 Financing cost (17,832 ) Convertible note --- Notes payable and bank loans, long-term portion $ 55,000 The discounts resulting from the original issue discount, warrants and embedded conversion feature are being amortized over the life of the $55k Note. Amortization expense related to these discounts in each of the three and nine months ended September 30, 2017 was $2,863. No amortization expense was recognized during 2016 related to the $55k Note. As of September 30, 2017, the unamortized discount was $52,137. As of September 30, 2017, the $55k Note was convertible into 381,944 of the Company’s common shares, based on a 40% discount to the last sale price of the Company’s common stock of $0.24 on September 30, 2017. During the nine months ended September 30, 2017 and 2016, the Company made no repayments on the $55k Note. During the three and nine months ended September 30, 2017 and 2016, the Company recorded interest expense on the $55k Note totaling $286 and $286, respectively. No interest expense was recognized on this note in 2016.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2017
Derivative Financial Instruments [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS	NOTE 10 – DERIVATIVE FINANCIAL INSTRUMENTS Derivative financial instruments are comprised of the fair value of conversion features embedded in convertible promissory issued in 2017 for which the conversion rate is not fixed, but instead is adjusted based on a discount to the market price of the Company’s common stock. The fair market value of the derivative liabilities was calculated at inception of each of the $53k Note, the $35k Note and the $55k Note and allocated to the respective convertible notes, with any excess recorded as a charge to “Financing cost.” The derivative financial instruments are then revalued at the end of each period, with the change in value recorded to “Change in fair value of on derivative financial instruments.” Derivative financial instruments recorded in the three and nine months ended September 30, 2017 include the following: Change in Fair Fair Derivative Value at Value at Financial September 30, Inception Instruments 2017 $53k Note ECF $ 58,154 $ (4,769 ) $ 53,385 $35k Note ECF 38,338 (578 ) 37,760 $55k Note ECF 65,332 (65 ) 65,267 $ 161,824 $ (5,412 ) $ 156,412 Fair market value of the derivative financial instruments is measured using the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.21-1.31%, expected life of 0.54-1.00 years, volatility of 175.1-183.6%, and expected dividend yield of zero. The entire amount of derivative instrument liabilities is classified as current due to the fact that settlement of the derivative instruments could be required within twelve months of the balance sheet date.

Shareholders' Deficit

Shareholders' Deficit	9 Months Ended
	Sep. 30, 2017
Shareholders' Deficit [Abstract]
SHAREHOLDERS' DEFICIT	NOTE 11 – SHAREHOLDERS’ DEFICIT Issuance of Common Stock During the nine months ended September 30, 2017, the Company sold 4,412,498 shares of common stock in private placement transactions to 15 investors. The Company received $533,000 in proceeds from the sales. The shares were issued at a share price between $0.10 and $0.30 per share. During the three months ended September 30, 2017, the Company issued 57,016 common shares pursuant to draws made by the Company under the Investment Agreement. The Company received $15,356 in proceeds from the draws. During August 2017, the Company issued 276,850 shares to a consultant. Common Stock Issuable As of September 30, 2017 and December 31, 2016, the Company was obligated to issue 10,313 and 80,643 shares of common stock, respectively, in exchange for professional services provided by a third party consultant during the further quarter of 2016 and the first eight months of 2017. During the three and nine months ended September 30, 2017, the Company recognized expense related to shares earned by the consultant of $17,705 and $46,669, respectively. During August 2017, 276,850 shares were issued to the consultant with a value of $49,996, in satisfaction of shares accrued through August 25, 2017. Stock Warrants Transactions involving our stock warrants during the nine months ended September 30, 2017 are summarized as follows: Weighted Average Exercise Number Price Outstanding at beginning of the period 10,576,389 $ 0.08 Granted during the period 8,990,000 $ 0.40 Exercised during the period --- $ --- Terminated during the period --- $ --- Outstanding at end of the period 19,566,389 $ 0.23 Exercisable at end of the period 19,566,389 $ 0.23 Weighted average remaining life 4.5 years The following table summarizes information about the Company’s stock warrants outstanding as of September 30, 2017: Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.05 to 0.09 8,388,889 4.6 $ 0.08 8,388,889 $ 0.08 $ 0.10 to 0.15 2,687,500 3.9 $ 0.11 2,687,500 $ 0.11 $ 0.25 to 0.50 7,300,000 4.5 $ 0.33 7,300,000 $ 0.33 $ 0.51 to 1.00 1,190,000 4.5 $ 0.97 1,190,000 $ 0.97 $ 0.05 to 1.00 19,566,389 4.5 $ 0.23 19,566,389 $ 0.23 During the nine months ended September 30, 2017, the Company issued 8,990,000 warrants. The fair value of the warrant was calculated using the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 1.74% to 1.95%, expected life of 5 years, volatility of 40 - 190.86%, and expected dividend yield of zero. The aggregate grant date fair value of warrants issued during the nine months ended September 30, 2017 was $496,132. Employee Equity Incentive Plan On January 1, 2016, the Company instituted the Employee Equity Incentive Plan (the “EIP”) for the purpose of having equity awards available to allow for equity participation by its employees. The EIP allows for the issuance of up to 15,503,680 shares of the Company’s common stock to employees, which may be issued in the form of stock options, stock appreciation rights, or restricted shares. The EIP is governed by the Company’s board, or a committee that may be appointed by the board in the future. During August 2017, the Company issued 207,500 shares of common stock to employees under the EIP as a result of grants made in 2016 that vested during 2017. The following table summarizes the status of shares issued and outstanding under the EIP outstanding as of and for the nine months ended September 30, 2017: Outstanding at beginning of the period 1,552,500 Granted during the period --- Terminated during the period (228,750 ) Outstanding at end of the period 1,323,750 Shares vested at period-end 795,000 Weighted average grant date fair value of shares granted during the period $ --- Aggregate grant date fair value of shares granted during the period $ --- Shares available for grant pursuant to EIP at period-end 11,829,934 Total stock based compensation recognized for grants under the EIP was $2,435 and $3,030 during the three months ended September 30, 2017 and 2016, respectively. Total stock based compensation recognized for grants under the EIP was $8,215 and $9,090 during the nine months ended September 30, 2017 and 2016, respectively. Total unrecognized stock compensation related to these grants was $31,655 as of September 30, 2017. A summary of the status of non-vested shares issued pursuant to the EIP as of September 30, 2017 presented below: Weighted Average Grant Date Shares Fair Value Nonvested at January 1, 2017 940,000 $ 0.04 Granted --- $ --- Vested (182,500 ) $ 0.04 Forfeited (228,750 ) $ 0.04 Nonvested at September 30, 2017 528,750 $ 0.04 Employee Stock Options The following table summarizes the status of options outstanding as of and for the nine months ended September 30, 2017: Weighted Average Exercise Number Price Outstanding at beginning of the period 2,349,996 $ 0.12 Granted during the period --- $ --- Exercised during the period --- $ --- Terminated during the period --- $ --- Outstanding at end of the period 2,349,996 $ 0.12 Options exercisable at period-end 462,500 Weighted average remaining life (in years) 8.9 Weighted average grant date fair value of options granted during the period $ --- Options available for grant at period-end 11,829,934 The following table summarizes information about the Company’s stock options outstanding as of September 30, 2017: Options Outstanding Options Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.08 1,600,000 8.8 $ 0.08 100,000 $ 0.08 $ 0.20 749,996 9.2 $ 0.20 --- $ --- $ 0.08 to 0.20 2,349,996 8.9 $ 0.12 100,000 $ 0.08 Total stock based compensation recognized related to option grants was $2,235 and $2,396 during the three months ended September 30, 2017 and 2016. Total stock based compensation recognized related to option grants was $7,504 and $2,396 during the nine months ended September 30, 2017 and 2016. A summary of the status of non-vested options issued pursuant to the EIP as of September 30, 2017 is presented below: Weighted Average Grant Date Shares Fair Value Nonvested at January 1, 2017 2,249,996 $ 0.03 Granted --- $ --- Vested (362,500 ) $ --- Forfeited --- $ --- Nonvested at September 30, 2017 1,887,496 $ 0.03

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES Service contracts The Company carries various service contracts on its office buildings & certain copier equipment for repairs, maintenance and inspections. All contracts are short term and can be cancelled. Litigation From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not aware of any such legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results. Leases The Company has two real estate leases in Naples, Florida. The Company entered into an operating lease for its main office in Naples, Florida beginning on August 1, 2013 and expiring July 31, 2020. The lease is for a 6901 square-foot space. The base rent for the first full year of the lease term is $251,287 per annum with increases during the period. The Company entered into another operating lease in the same building for an additional 361 square feet space for use of the medical equipment for the same period. The base rent for the first full year of the lease term is $13,140 per annum. During the nine months ended September 30, 2017, the Company entered into an agreement with MOD pursuant to which the Company will pay rent to MOD in the amount of $2,040 per month for office space in MOD’s facility used by the Company and its employees. The agreement is effective from January 1, 2017 through July 31, 2018. During the three and nine months ended September 30, 2017, the Company recognized rent expense related to the marketing agreement in the amount of $6,120 and $18,360, respectively, pursuant to this agreement and had prepaid an additional $4,929 toward future rent as of September 30, 2017. Total lease expense for the three months ended September 30, 2017 and 2016 was $77,636 and $78,940, respectively. Total lease expense for the nine months ended September 30, 2017 and 2016 was $217,926 and $266,021, respectively. Future minimum lease payments (excluding real estate taxes and maintenance costs) as of September 30, 2017 are as follows: 2017 (October to December) $ 72,227 2018 281,460 2019 273,856 2020 162,055 2021 --- Total $ 789,598 Employment/Consulting Agreements The Company has employment agreements with each of its four physicians. The agreements generally call for a fixed salary at the beginning of the contract with a transaction to performance based pay later in the contract. The contracts expire at various times through 2019, with early termination available upon a notice period of 30-90 days during which compensation is paid to the physician but NWC has no further severance obligation. During 2016, DMD retired from practice to focus on his duties as CEO of HLYK. On July 1, 2016, HLYK entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or HLYK. If Dr. Dent’s employment is terminated by HLYK (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination. On July 1, 2016, HLYK entered into an agreement with Mr. George O’Leary, HLYK’s Chief Financial Officer and a member of the Board of Directors, extending his prior agreement with the Company. Mr. O’Leary’s employment agreement continues until terminated by Mr. O’Leary or HLYK. If Mr. O’Leary employment is terminated by HLYK (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Mr. O’Leary will be entitled to receive his base salary and the Company shall maintain his employee benefits for a period of twelve (12) months beginning on the date of termination. In the event that Mr. O’Leary terminates the agreement, he shall be entitled to any accrued by unpaid salary and other benefits up to and including the date of termination.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 13 – SEGMENT REPORTING The Company has two reportable segments: NWC and HLYK. NWC is a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice. The practice’s office is located in Naples, Florida. HLYK plans to operate an online personal medical information and record archive system, the “HealthLynked Network”, which will enable patients and doctors to keep track of medical information via the Internet in a cloud based system. Patients will complete a detailed online personal medical history including past surgical history, medications, allergies, and family history. Once this information is entered patients and their treating physicians will be able to update the information as needed to provide a comprehensive medical history. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Segment information for the three months ended September 30, 2017 and 2016 was as follows: Three Months Ended September 30, 2017 Three Months Ended September 30, 2016 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 480,723 $ --- $ 480,723 $ 499,448 $ --- $ 499,448 Operating Expenses Salaries and benefits 345,895 160,311 506,206 347,242 85,707 432,949 General and administrative 228,278 252,336 480,614 273,416 239,988 513,404 Depreciation and amortization 5,601 455 6,056 5,718 --- 5,718 Total Operating Expenses 579,774 413,102 992,876 626,376 325,695 952,071 Loss from operations $ (99,051 ) $ (413,102 ) $ (512,153 ) $ (126,928 ) $ (325,695 ) $ (452,623 ) Other Segment Information Interest expense $ 5,723 $ 21,401 $ 27,124 $ 4,442 $ 8,967 $ 13,409 Loss on extinguishment of debt $ --- $ 290,581 $ 290,581 $ --- $ --- $ --- Financing cost $ --- $ 32,324 $ 32,324 $ --- $ --- $ --- Amortization of original issue and debt discounts on convertible notes $ --- $ 63,552 $ 63,552 $ --- $ 100,187 $ 100,187 Proceeds from settlement of lawsuit $ --- $ --- $ --- $ 38,236 $ --- $ 38,236 Change in fair value of derivative financial instruments $ --- $ 5,412 $ 5,412 $ --- $ --- $ --- As of September 30, 2017 As of December 31, 2016 Identifiable assets $ 217,344 $ 151,538 $ 368,882 $ 240,115 $ 89,396 $ 329,511 During the three months ended September 30, 2017, HLYK recognized revenue of $2,377 related to subscription revenue billed to and paid for by NWC physicians for access to the HealthLynked Network, which the Company test-launched during the third quarter of 2017. The revenue for HLYK and related expense for NWC were eliminated on consolidation. Segment information for the nine months ended September 30, 2017 and 2016 was as follows: Nine Months Ended September 30, 2017 Nine Months Ended September 30, 2016 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 1,473,639 $ --- $ 1,473,639 $ 1,515,293 $ --- $ 1,515,293 Operating Expenses Salaries and benefits 1,025,333 443,878 1,469,211 1,001,838 132,235 1,134,073 General and administrative 619,112 749,906 1,369,018 825,603 322,961 1,148,564 Depreciation and amortization 16,858 765 17,623 15,804 --- 15,804 Total Operating Expenses 1,661,303 1,194,549 2,855,852 1,843,245 455,196 2,298,441 Loss from operations $ (187,664 ) $ (1,194,549 ) $ (1,382,213 ) $ (327,952 ) $ (455,196 ) $ (783,148 ) Other Segment Information Interest expense $ 17,086 $ 47,835 $ 64,921 $ 15,424 $ 8,967 $ 24,391 Loss on extinguishment of debt $ --- $ 290,581 $ 290,581 $ --- $ --- $ --- Financing cost $ --- $ 32,324 $ 32,324 $ --- $ --- $ --- Amortization of original issue and debt discounts on convertible notes $ --- $ 194,120 $ 194,120 $ --- $ 100,187 $ --- Proceeds from settlement of lawsuit $ --- $ --- $ --- $ 38,236 $ --- $ 38,236 Change in fair value of derivative financial instruments $ --- $ 5,412 $ 5,412 $ --- $ --- $ --- During the nine months ended September 30, 2017, HLYK recognized revenue of $2,377 related to subscription revenue billed to and paid for by NWC physicians for access to the HealthLynked Network, which the Company test-launched during the third quarter of 2017. The revenue for HLYK and related expense for NWC were eliminated on consolidation.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENTS On October 5, 2017, the Company sold 211,111 shares of common stock, as well as a five-year warrant to purchase an additional 126,666 shares at an exercise price of $0.30 per share, to one investor. The Company received $38,000 in proceeds from the sale. The shares were issued at a share price of $0.18 per share. On October 18, 2017, the Company sold 250,000 shares of common stock, as well as a five-year warrant to purchase an additional 166,666 shares at an exercise price of $0.30 per share, to one investor. The Company received $50,000 in proceeds from the sale. The shares were issued at a share price of $0.20 per share. On October 23, 2017, the Company entered into a securities purchase agreement for the sale of a $53,000 convertible note to PULG. The note has an interest rate of 10% and a default interest rate of 22%. The note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due. On October 27, 2017, the Company entered into a securities purchase agreement for the sale of a $171,500 convertible note to an individual lender. Net proceeds to the Company were $150,000. The note has an interest rate of 10% and a default interest rate of 22%. The note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 35% discount to the lowest closing bid price during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due. On November 1, 2017, the Company sold 1,000,000 shares of common stock, par value $0.0001, to an accredited investor at a purchase price of $0.20 per share. Net proceeds to the Company were $200,000. The investor was also granted a five-year warrant to purchase 666,666 shares of the Company’s common stock at an exercise price of $0.30 per share.

Significant Accounting Polici21

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets and useful life of fixed assets.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Patient service revenues are recognized at the time of service for the net amount expected to be collected. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement purposes, the Company considers all highly-liquid investments with original maturities of three months or less to be cash and cash equivalents.
Accounts receivable	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 45% of total billings. Trade accounts receivable are recorded at this net amount. As of September 30, 2017 and December 31, 2016, the Company’s gross accounts receivable were $269,501 and $333,804, respectively, and net accounts receivable were $118,581 and $146,874, respectively, based upon net reporting of accounts receivable.
Capital Leases	Capital Leases Costs associated with capitalized leases are capitalized and depreciated ratably over the term of the related useful life of the asset and/or the capital lease term. The related depreciation for the three months ended September 30, 2017 and 2016 was $4,587 and $4,587, respectively. The related depreciation for the nine months ended September 30, 2017 and 2016 was $13,761 and $13,761, respectively. Accumulated depreciation of capitalized leases was $299,151 and $285,390 at September 30, 2017 and December 31, 2016, respectively.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. There was no impairment as of September 30, 2017 and December 31, 2016.
Convertible Notes	Convertible Notes Convertible notes are regarded as compound instruments, consisting of a liability component and an equity component. The component parts of compound instruments are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortized cost basis until extinguished upon conversion or at the instrument’s maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized as additional paid-in capital and included in equity, net of income tax effects, and is not subsequently remeasured. After initial measurement, they are carried at amortized cost using the effective interest method.
Derivative Financial Instruments	Derivative Financial Instruments The Company reviews the terms of convertible debt, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received, an immediate charge to income is recognized, in order to initially record the derivative instrument liabilities at their fair value. The discount from the face value of convertible debt instruments resulting from allocating some or all of the proceeds to the derivative instruments is amortized over the life of the instrument through periodic charges to income. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Fair Value of Assets and Liabilities	Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – ● Level 2 ● Level 3 The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods.
Income Taxes	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Recurring Fair Value Measurements	Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, short-term borrowings, accounts payable, accrued liabilities, and derivative financial instruments approximated their fair value.
Net Income (Loss) per Share	Net Income (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three and nine month periods ended September 30, 2017 and 2016, the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of September 30, 2017 and 2016, potentially dilutive securities were comprised of (i) 19,566,389 and 10,576,389 warrants outstanding, respectively, (ii) 2,349,996 and 1,600,000 stock options outstanding, respectively, (iii) 8,675,180 and 7,375,000 shares issuable upon conversion of convertible notes, respectively, and (iv) 528,750 and 940,000 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842). The effective date for ASU 2017-13 is for fiscal years beginning after December 15, 2018. We are currently evaluating the impact of adopting ASU 2017-13 on our unaudited consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350), which simplifies the goodwill impairment test. The effective date for ASU 2017-04 is for fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We are currently evaluating the impact of adopting ASU 2017-04 on our unaudited condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for the Company on January 1, 2018; however, early adoption is permitted with prospective application to any business development transaction. We are currently evaluating the impact of adopting ASU 2017-04 on our unaudited condensed consolidated financial statements. The Company applied ASU 2015-03: Interest – Imputation of Interest, which simplifies the presentation of debt issuance costs, and netted debt issue costs previously reported as assets with the related liability for presentation purposes. On May 28, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers. The standard will eliminate the transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. The Company intends to adopt this guidance for the year ended December 31, 2017. The Company has not yet evaluated the impact the adoption this standard will have on its results of operations upon adoption. In August 2014, the FASB issued ASU No. 2014-15 Presentation of Financial Statements-Going Concern. The amendments in this update apply to all reporting entities and require an entity’s management, in connection with preparing financial statements for each annual and interim reporting period, to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). This ASU is effective for annual periods ending after December 15, 2016. The Company adopted this standard for the year ended December 31, 2016. Based on the results of our analysis, no additional disclosures were required. The Company has evaluated recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC and we have not identified any that would have a material impact on the Company’s financial position, or statements.

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Property, Plant, and Equipment [Abstract]
Schedule of property plant and equipment	September 30, December 31, 2017 2016 (audited) Capital Lease equipment $ 343,492 $ 343,492 Telephone equipment 12,308 12,308 Furniture, Transport and Office equipment 433,059 419,821 Total Property, plant and equipment 788,859 775,621 Less: accumulated depreciation (722,407 ) (704,785 ) Property, plant and equipment, net $ 66,452 $ 70,836

Due to Related Party (Tables)

Due to Related Party (Tables)	9 Months Ended
	Sep. 30, 2017
Due to Related Party [Abstract]
Schedule of amounts due to related parties	September 30, December 31, 2017 2016 (audited) Current portion: Notes payable and accrued interest, Dr. Michael Dent $ 320,011 $ --- Deferred compensation, Dr. Michael Dent 300,600 300,600 Due to MedOffice Direct --- 11,192 Total current portion 620,611 311,792 Long term portion: Notes payable and accrued interest, Dr. Michael Dent 253,242 237,157 Total due to related parties $ 873,853 $ 548,949
Schedule of amount borrowed under unsecured promissory notes	Inception Date Maturity Date Interest Rate Amount January 12, 2017 January 13, 2018 10 % $ 35,000 January 18, 2017 January 19, 2018 10 % 20,000 January 24, 2017 January 15, 2018 10 % 50,000 February 9, 2017 February 10, 2018 10 % 30,000 April 20, 2017 April 21, 2018 15 % 10,000 June 15, 2017 June 16, 2018 10 % 32,500 August 17, 2017 August 18, 2018 10 % 20,000 August 24, 2017 August 25, 2018 10 % 37,500 September 7, 2017 September 8, 2018 10 % 35,000 September 21, 2017 September 22, 2018 10 % 26,500 September 29, 2017 September 30, 2018 10 % 12,000 $ 308,500

Capital Lease (Tables)

Capital Lease (Tables)	9 Months Ended
	Sep. 30, 2017
Capital Lease/Notes Payable/Convertible Notes Payable [Abstract]
Schedule of capital lease obligations	September 30, December 31, 2017 2016 (audited) Note payable, New Everbank Lease $ 44,341 $ 58,102 Less: note payable, New Everbank Lease (Capital leases), current portion (18,348 ) (18,348 ) Notes payable, bank loans and capital leases, long-term portion $ 25,993 $ 39,754
Schedule of future minimum payments to capital leases	2017 (October to December) $ 4,587 2018 18,348 2019 18,348 2020 3,058 2021 --- Total $ 44,341

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2017
Short-term Debt [Line Items]
Schedule of notes payable	September 30, December 31, 2017 2016 (audited) Face Value $550k Note - July 2016 $ 550,000 $ 550,000 $50k Note - July 2016 50,000 50,000 $111k Note - May 2017 111,000 --- $53k Note - July 2017 53,000 --- $35k Note - September 2017 35,000 --- $55k Note - September 2017 55,000 --- 854,000 600,000 Unamortized Discount $550k Note - July 2016 $ --- $ (96,631 ) $50k Note - July 2016 --- (17,701 ) $111k Note - May 2017 (35,917 ) --- $53k Note - July 2017 (37,423 ) --- $35k Note - September 2017 (32,135 ) --- $55k Note - September 2017 (52,137 ) --- (157,612 ) (114,332 ) Net Book Value $550k Note - July 2016 $ 550,000 $ 453,369 $50k Note - July 2016 50,000 32,299 $111k Note - May 2017 75,083 --- $53k Note - July 2017 15,577 --- $35k Note - September 2017 2,865 --- $55k Note - September 2017 2,863 --- Convertible notes payable, net of original issue discount and debt discount $ 696,388 $ 485,668
Convertible Notes Payable - July 2016 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Original issue discount $ 50,000 Warrants 111,479 Embedded conversion feature 161,479 Convertible note 227,042 Face value of convertible note $ 550,000
Convertible Notes Payable - May 2017 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Original issue discount $ 11,000 Warrants 27,595 Embedded conversion feature 38,595 Convertible note 33,810 Notes payable and bank loans, long-term portion $ 111,000
Convertible Notes Payable - July 2017 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 58,154 Original issue discount 3,000 Financing cost (8,154 ) Convertible note --- Notes payable and bank loans, long-term portion $ 53,000
Convertible Notes Payable - September 2017 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 38,338 Original issue discount 3,000 Financing cost (6,338 ) Convertible note --- Notes payable and bank loans, long-term portion $ 35,000
Convertible Notes Payable Two - September 2017 [Member]
Short-term Debt [Line Items]
Schedule of allocation of proceeds at inception	Embedded conversion feature $ 65,332 Original issue discount 7,500 Financing cost (17,832 ) Convertible note --- Notes payable and bank loans, long-term portion $ 55,000

Derivative Financial Instrume26

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2017
Derivative Financial Instruments [Abstract]
Schedule of derivative financial instruments	Change in Fair Fair Derivative Value at Value at Financial September 30, Inception Instruments 2017 $53k Note ECF $ 58,154 $ (4,769 ) $ 53,385 $35k Note ECF 38,338 (578 ) 37,760 $55k Note ECF 65,332 (65 ) 65,267 $ 161,824 $ (5,412 ) $ 156,412

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2017
Option Indexed to Issuer's Equity [Line Items]
Schedule of stock warrants	Weighted Average Exercise Number Price Outstanding at beginning of the period 10,576,389 $ 0.08 Granted during the period 8,990,000 $ 0.40 Exercised during the period --- $ --- Terminated during the period --- $ --- Outstanding at end of the period 19,566,389 $ 0.23 Exercisable at end of the period 19,566,389 $ 0.23 Weighted average remaining life 4.5 years
Summary of shares issued and outstanding under the EIP outstanding	Outstanding at beginning of the period 1,552,500 Granted during the period --- Terminated during the period (228,750 ) Outstanding at end of the period 1,323,750 Shares vested at period-end 795,000 Weighted average grant date fair value of shares granted during the period $ --- Aggregate grant date fair value of shares granted during the period $ --- Shares available for grant pursuant to EIP at period-end 11,829,934
Schedule of stock options outstanding	Weighted Average Exercise Number Price Outstanding at beginning of the period 2,349,996 $ 0.12 Granted during the period --- $ --- Exercised during the period --- $ --- Terminated during the period --- $ --- Outstanding at end of the period 2,349,996 $ 0.12 Options exercisable at period-end 462,500 Weighted average remaining life (in years) 8.9 Weighted average grant date fair value of options granted during the period $ --- Options available for grant at period-end 11,829,934
Warrant [Member]
Option Indexed to Issuer's Equity [Line Items]
Schedule of stock warrants outstanding	Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.05 to 0.09 8,388,889 4.6 $ 0.08 8,388,889 $ 0.08 $ 0.10 to 0.15 2,687,500 3.9 $ 0.11 2,687,500 $ 0.11 $ 0.25 to 0.50 7,300,000 4.5 $ 0.33 7,300,000 $ 0.33 $ 0.51 to 1.00 1,190,000 4.5 $ 0.97 1,190,000 $ 0.97 $ 0.05 to 1.00 19,566,389 4.5 $ 0.23 19,566,389 $ 0.23
Employee Stock Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Schedule of stock warrants outstanding	Options Outstanding Options Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.08 1,600,000 8.8 $ 0.08 100,000 $ 0.08 $ 0.20 749,996 9.2 $ 0.20 --- $ --- $ 0.08 to 0.20 2,349,996 8.9 $ 0.12 100,000 $ 0.08
Summary of nonvested shares issued	Weighted Average Grant Date Shares Fair Value Nonvested at January 1, 2017 2,249,996 $ 0.03 Granted --- $ --- Vested (362,500 ) $ --- Forfeited --- $ --- Nonvested at September 30, 2017 1,887,496 $ 0.03
Employee Equity Incentive Plan [Member]
Option Indexed to Issuer's Equity [Line Items]
Summary of nonvested shares issued	Weighted Average Grant Date Shares Fair Value Nonvested at January 1, 2017 940,000 $ 0.04 Granted --- $ --- Vested (182,500 ) $ 0.04 Forfeited (228,750 ) $ 0.04 Nonvested at September 30, 2017 528,750 $ 0.04

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies [Abstract]
Schedule of future minimum lease payments	2017 (October to December) $ 72,227 2018 281,460 2019 273,856 2020 162,055 2021 --- Total $ 789,598

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Schedule of segment information	Three Months Ended September 30, 2017 Three Months Ended September 30, 2016 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 480,723 $ --- $ 480,723 $ 499,448 $ --- $ 499,448 Operating Expenses Salaries and benefits 345,895 160,311 506,206 347,242 85,707 432,949 General and administrative 228,278 252,336 480,614 273,416 239,988 513,404 Depreciation and amortization 5,601 455 6,056 5,718 --- 5,718 Total Operating Expenses 579,774 413,102 992,876 626,376 325,695 952,071 Loss from operations $ (99,051 ) $ (413,102 ) $ (512,153 ) $ (126,928 ) $ (325,695 ) $ (452,623 ) Other Segment Information Interest expense $ 5,723 $ 21,401 $ 27,124 $ 4,442 $ 8,967 $ 13,409 Loss on extinguishment of debt $ --- $ 290,581 $ 290,581 $ --- $ --- $ --- Financing cost $ --- $ 32,324 $ 32,324 $ --- $ --- $ --- Amortization of original issue and debt discounts on convertible notes $ --- $ 63,552 $ 63,552 $ --- $ 100,187 $ 100,187 Proceeds from settlement of lawsuit $ --- $ --- $ --- $ 38,236 $ --- $ 38,236 Change in fair value of derivative financial instruments $ --- $ 5,412 $ 5,412 $ --- $ --- $ --- As of September 30, 2017 As of December 31, 2016 Identifiable assets $ 217,344 $ 151,538 $ 368,882 $ 240,115 $ 89,396 $ 329,511 Nine Months Ended September 30, 2017 Nine Months Ended September 30, 2016 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 1,473,639 $ --- $ 1,473,639 $ 1,515,293 $ --- $ 1,515,293 Operating Expenses Salaries and benefits 1,025,333 443,878 1,469,211 1,001,838 132,235 1,134,073 General and administrative 619,112 749,906 1,369,018 825,603 322,961 1,148,564 Depreciation and amortization 16,858 765 17,623 15,804 --- 15,804 Total Operating Expenses 1,661,303 1,194,549 2,855,852 1,843,245 455,196 2,298,441 Loss from operations $ (187,664 ) $ (1,194,549 ) $ (1,382,213 ) $ (327,952 ) $ (455,196 ) $ (783,148 ) Other Segment Information Interest expense $ 17,086 $ 47,835 $ 64,921 $ 15,424 $ 8,967 $ 24,391 Loss on extinguishment of debt $ --- $ 290,581 $ 290,581 $ --- $ --- $ --- Financing cost $ --- $ 32,324 $ 32,324 $ --- $ --- $ --- Amortization of original issue and debt discounts on convertible notes $ --- $ 194,120 $ 194,120 $ --- $ 100,187 $ --- Proceeds from settlement of lawsuit $ --- $ --- $ --- $ 38,236 $ --- $ 38,236 Change in fair value of derivative financial instruments $ --- $ 5,412 $ 5,412 $ --- $ --- $ ---

Business and Business Present30

Business and Business Presentation (Details) - shares	1 Months Ended
	Sep. 05, 2014	Sep. 30, 2017	Dec. 31, 2016	Sep. 03, 2014
Business and Business Presentation (Textual)
Common stock, shares authorized		230,000,000	230,000,000	230,000,000
Preferred stock, shares authorized				20,000,000
Stock issued during period shares acquisitions	50,000,000
Shares authorized				250,000,000
Share Exchange Agreement [Member]
Business and Business Presentation (Textual)
Equity method investment ownership percentage	100.00%

Significant Accounting Polici31

Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Significant Accounting Policies (Textual)
Percentage of customers accounts receivable billings			45.00%
Accumulated depreciation of capitalized leases	$ 299,151		$ 299,151		$ 285,390
Accounts receivable gross	269,501		269,501		333,804
Accounts receivable net	118,581		118,581		$ 146,874
Depreciation of capitalized leases	$ 4,587	$ 4,587	$ 13,761	$ 13,761
Convertible notes [Member]
Significant Accounting Policies (Textual)
Antidilutive securities			8,675,180	7,375,000
Stock options [Member]
Significant Accounting Policies (Textual)
Antidilutive securities			2,349,996	1,600,000
Warrants [Member]
Significant Accounting Policies (Textual)
Antidilutive securities			19,566,389	10,576,389
Unissued shares [Member]
Significant Accounting Policies (Textual)
Antidilutive securities			528,750	940,000
Minimum [Member]
Significant Accounting Policies (Textual)
Estimated useful lives			5 years
Maximum [Member]
Significant Accounting Policies (Textual)
Estimated useful lives			7 years
Accounts receivable [Member]
Significant Accounting Policies (Textual)
Concentration risk, percentage			10.00%

Going Concern Matters and Liq32

Going Concern Matters and Liquidity (Details) - USD ($)	Oct. 05, 2017	Oct. 18, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Going Concern Matters and Liquidity (Textual)
Working capital deficit					$ 1,536,307
Accumulated deficit			$ (4,082,966)		(4,082,966)		$ (2,124,219)
Net loss			$ (920,322)	$ (527,983)	(1,958,747)	$ (869,490)
Net cash used by operating activities					(1,131,324)	(496,441)
Net cash used in investing activities					(13,238)	(12,611)
Net cash provided by financing activities					1,102,021	803,486
Proceeds from sale of common stock					$ 548,356	374,000
Sale of common stock shares					4,469,514
Related party loans					$ 308,470	176,500
Net proceeds from issuance of convertible notes					229,500	$ 475,000
Convertible promissory note [Member]
Going Concern Matters and Liquidity (Textual)
Proceeds from sale of common stock					$ 200,000
Sale of common stock shares					1,000,000
Net proceeds from issuance of convertible notes					$ 150,000
Warrant to purchase shares of common stock					666,666
Common stock at an exercise price			$ 0.30		$ 0.30
Warrant terms					5 years
HLYK [Member]
Going Concern Matters and Liquidity (Textual)
Proceeds from sale of common stock					$ 15,356		$ 374,000
Sale of common stock shares					57,016		6,167,500
Net proceeds from issuance of convertible notes							$ 475,000
Debt Instrument, Maturity Date					Jan. 22, 2018
Convertible notes maturity date, description					The Company expects to repay its outstanding convertible notes of which $111,000 face value matures on January 22, 2018, $53,000 on April 15, 2018, $35,000 on June 15, 2018, $550,000 on July 7, 2018, and $50,000 on July 11, 2018, and $55,000 on September 11, 2018 from outside funding sources, including but not limited to amounts available upon the exercise of the put rights granted to the Company under the Investment Agreement, sales of equity, loans from related parties and others or through the conversion of the notes into equity.
Investor agreed to purchase of common stock							$ 3,000,000
Subsequent Events [Member]
Going Concern Matters and Liquidity (Textual)
Common stock at an exercise price	$ 0.30	$ 0.30
Warrant terms	5 years	5 years

Deferred Offering Costs (Detail

Deferred Offering Costs (Details)	Jun. 07, 2017USD ($)$ / sharesshares	Mar. 22, 2017USD ($)shares	Jul. 07, 2016USD ($)Days$ / shares	Sep. 30, 2017USD ($)$ / shares	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)$ / shares	Sep. 30, 2016USD ($)	Dec. 31, 2016$ / shares
Deferred Offering Costs (Textual)
Common stock par value, per share | $ / shares				$ 0.0001		$ 0.0001		$ 0.0001
General and Administrative Expense				$ 480,614	$ 513,404	$ 1,369,018	$ 1,148,564
Advisor [Member]
Deferred Offering Costs (Textual)
Warrants to purchase of common stock | shares	200,000
Warrants to purchase, per share | $ / shares	$ 0.25
Advisor One [Member]
Deferred Offering Costs (Textual)
Warrants to purchase of common stock | shares	100,000
Warrants to purchase, per share | $ / shares	$ 0.50
Advisor Two [Member]
Deferred Offering Costs (Textual)
Warrants to purchase of common stock | shares	50,000
Warrants to purchase, per share | $ / shares	$ 1
Investment Agreement [Member]
Deferred Offering Costs (Textual)
General and Administrative Expense				$ 12,802		$ 19,203
Investment Agreement [Member] | Accredited Investor [Member]
Deferred Offering Costs (Textual)
Amount invested to purchase of common stock			$ 3,000,000
Common stock par value, per share | $ / shares			$ 0.0001
Purchase price of shares, percentage			80.00%
Common stock, trading days | Days			5
Payments to purchase of common stock			$ 50,000
Warrants exercise prices, description			The warrants were to expire five (5) years from their respective grant dates and have an exercise price equal to 130% of the weighted average purchase price for the respective "$50,000 increment."
Warrants expiration, term			5 years
Warrants exercise price, percentage			130.00%
Amended Investment Agreement [Member] | Investor [Member]
Deferred Offering Costs (Textual)
Warrants exercise prices, description		(i) 4,000,000 shares at $0.25 per share; (ii) 2,000,000 shares at $0.50 per share; and (iii) 1,000,000 shares at $1.00 per share.
Fair value of warrants	$ 96,990	$ 56,635
Risk-free interest rate	1.74%	1.95%
Expected life (in years)	5 years	5 years
Expected volatility rate	40.00%	40.00%
Expected dividend yield	$ 0	$ 0
Granting the investor warrants to tender		$ 50,000
Warrants to purchase of common stock | shares		7,000,000

Property, Plant, and Equipmen34

Property, Plant, and Equipment (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	$ 788,859	$ 775,621
Less: accumulated depreciation	(722,407)	(704,785)
Property, plant and equipment, net	66,452	70,836
Capital Lease equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	343,492	343,492
Furniture, Transport and Office equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	433,059	419,821
Telephone equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	$ 12,308	$ 12,308

Property, Plant, and Equipmen35

Property, Plant, and Equipment (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Property, Plant, and Equipment (Textual)
Depreciation expense	$ 6,056	$ 5,718	$ 17,623	$ 15,804

Due to Related Party (Details)

Due to Related Party (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current portion:
Total current portion	$ 620,611	$ 311,792
Long term portion:
Long term portion	253,242	237,157
Total due to related parties	873,853	548,949
Notes payable and accrued interest, Dr. Michael Dent [Member]
Current portion:
Total current portion	320,011
Deferred compensation, Dr. Michael Dent [Member]
Current portion:
Total current portion	300,600	300,600
Due to MedOffice Direct [Member]
Current portion:
Total current portion		$ 11,192

Due to Related Party (Details 1

Due to Related Party (Details 1)	9 Months Ended
	Sep. 30, 2017USD ($)
Related Party Transaction [Line Items]
Issuance of unsecured promissory notes, Amount	$ 308,500
Dr. Michael Dent [Member] | Unsecured promissory note [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 12, 2017
Maturity Date	Jan. 13, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 35,000
Dr. Michael Dent [Member] | Unsecured promissory note one [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 18, 2017
Maturity Date	Jan. 19, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 20,000
Dr. Michael Dent [Member] | Unsecured promissory note two [Member]
Related Party Transaction [Line Items]
Inception Date	Jan. 24, 2017
Maturity Date	Jan. 15, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 50,000
Dr. Michael Dent [Member] | Unsecured promissory note three [Member]
Related Party Transaction [Line Items]
Inception Date	Feb. 9, 2017
Maturity Date	Feb. 10, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 30,000
Dr. Michael Dent [Member] | Unsecured promissory note four [Member]
Related Party Transaction [Line Items]
Inception Date	Apr. 20, 2017
Maturity Date	Apr. 21, 2018
Interest Rate	15.00%
Issuance of unsecured promissory notes, Amount	$ 10,000
Dr. Michael Dent [Member] | Unsecured promissory note five [Member]
Related Party Transaction [Line Items]
Inception Date	Jun. 15, 2017
Maturity Date	Jun. 16, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 32,500
Dr. Michael Dent [Member] | Unsecured promissory note six [Member]
Related Party Transaction [Line Items]
Inception Date	Aug. 17, 2017
Maturity Date	Aug. 18, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 20,000
Dr. Michael Dent [Member] | Unsecured promissory note seven [Member]
Related Party Transaction [Line Items]
Inception Date	Aug. 24, 2017
Maturity Date	Aug. 25, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 37,500
Dr. Michael Dent [Member] | Unsecured promissory note eight [Member]
Related Party Transaction [Line Items]
Inception Date	Sep. 7, 2017
Maturity Date	Sep. 8, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 35,000
Dr. Michael Dent [Member] | Unsecured promissory note nine [Member]
Related Party Transaction [Line Items]
Inception Date	Sep. 21, 2017
Maturity Date	Sep. 22, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 26,500
Dr. Michael Dent [Member] | Unsecured promissory note ten [Member]
Related Party Transaction [Line Items]
Inception Date	Sep. 29, 2017
Maturity Date	Sep. 30, 2018
Interest Rate	10.00%
Issuance of unsecured promissory notes, Amount	$ 12,000

Due to Related Party (Details T

Due to Related Party (Details Textual) - USD ($)	1 Months Ended			3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2014	Aug. 31, 2014	Dec. 31, 2013	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
Due to Related Party (Textual)
Issuance of unsecured promissory notes					$ 308,500
Balance of accrued interest on notes payable						$ 22,108
Interest accrued					38,192	22,108
Amount payable				$ 620,611	$ 620,611	311,792
Direct obligations paid						25,000
Dr. Michael Dent [Member]
Due to Related Party (Textual)
Maturity date, description					During January 2017, the note was again amended to extend the maturity date until December 31, 2018.
Increased on unsecured note payable	$ 750,000		$ 500,000
Dr. Michael Dent [Member] | NWC [Member]
Due to Related Party (Textual)
Issuance of unsecured promissory notes		$ 175,000
Interest rate		0.00%
MedOffice Direct (MOD) [Member]
Due to Related Party (Textual)
Amount payable						11,192
Rent paid for office space					$ 2,040
Additional amount towards future rent				4,929	4,929
Amount paid to agreement and prepaid				$ 6,120	$ 18,360
Maturity date, description					The agreement is effective from January 1, 2017 through July 31, 2018.
Direct obligations paid						13,808
2017 DMD Notes [Member]
Due to Related Party (Textual)
Interest rate					10.00%
Interest accrued					$ 11,511	$ 0

Capital Lease (Details)

Capital Lease (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Capital Lease/Notes Payable/Convertible Notes Payable [Abstract]
Note payable, New Everbank Lease	$ 44,341	$ 58,102
Less: note payable, New Everbank Lease (Capital leases), current portion	(18,348)	(18,348)
Notes payable, bank loans and capital leases, long-term portion	$ 25,993	$ 39,754

Capital Lease (Details 1)

Capital Lease (Details 1)	Sep. 30, 2017USD ($)
Capital Lease/Notes Payable/Convertible Notes Payable [Abstract]
2017 (October to December)	$ 4,587
2,018	18,348
2,019	18,348
2,020	3,058
2,021
Total	$ 44,341

Capital Lease (Details Textual)

Capital Lease (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Capital Lease (Textual)
Note payable - capital leases		$ 25,993		$ 39,754
Payments on capital leases		13,761	$ 13,761
Everbank [Member]
Capital Lease (Textual)
Note payable - capital leases expiration date	Mar. 31, 2020
Note payable - capital leases		$ 48,928
Note payable - capital leases monthly payment	$ 1,529
Note payable - capital leases terms	60 months

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Aug. 09, 2017	Jul. 11, 2017	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
Notes Payable (Textual)
Discount against the note payable			$ 19,226	$ 19,226	$ 0
Note payable			50,352	50,352
Power Up Lending Group, Ltd. [Member] | Merchant Cash Advance Factoring Agreement [Member]
Notes Payable (Textual)
Advance received for factoring agreement		$ 26,000
Description of payables in factoring agreement		The Company is required to repay the advance, which acts like an ordinary note payable, at the rate of $1,372 per week until the balance of $34,580 has been repaid.
Discount against the note payable		$ 9,550
Amortization of the discount			4,227	4,227
Note payable		$ 34,580	14,162	14,162
Power Up Lending Group, Ltd. [Member] | Merchant Cash Advance Factoring Agreement [Member]
Notes Payable (Textual)
Advance received for factoring agreement	$ 51,000
Description of payables in factoring agreement	The Company is required to repay the advance, which acts like an ordinary note payable, at the rate of $2,752 per week until the balance of $69,360 has been repaid.
Discount against the note payable	$ 19,380
Amortization of the discount			5,477	5,477
Note payable	$ 69,360		$ 36,190	$ 36,190

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2017	Sep. 11, 2017	Sep. 07, 2017	Jul. 10, 2017	May 22, 2017	Dec. 31, 2016	Jul. 07, 2016
Debt Instrument [Line Items]
Face Value	$ 854,000					$ 600,000
Unamortized Discount	(157,612)					(114,332)
Net Book Value	696,388					485,668
$550k Note - July 2016 [Member]
Debt Instrument [Line Items]
Face Value	550,000					550,000	$ 550,000
Unamortized Discount	0					(96,631)
Net Book Value	550,000					453,369
$50k Note - July 2016 [Member]
Debt Instrument [Line Items]
Face Value	50,000					50,000
Unamortized Discount						(17,701)
Net Book Value	50,000					32,299
$111k Note - May 2017 [Member]
Debt Instrument [Line Items]
Face Value	111,000				$ 111,000
Unamortized Discount	(35,917)
Net Book Value	75,083
$53k Note - July 2017 [Member]
Debt Instrument [Line Items]
Face Value	53,000			$ 53,000
Unamortized Discount	(37,423)
Net Book Value	15,577
$35k Note - September 2017 [Member]
Debt Instrument [Line Items]
Face Value	35,000		$ 35,000
Unamortized Discount	(32,135)
Net Book Value	2,865
$55k Note - September 2017 [Member]
Debt Instrument [Line Items]
Face Value	55,000	$ 55,000
Unamortized Discount	(52,137)
Net Book Value	$ 2,863

Convertible Notes Payable (De44

Convertible Notes Payable (Details 1) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Short-term Debt [Line Items]
Notes payable and bank loans, long-term portion convertible note	$ 854,000	$ 600,000
Convertible Notes Payable - July 2016 [Member]
Short-term Debt [Line Items]
Original issue discount	50,000
Warrants	111,479
Embedded conversion feature	161,479
Convertible note	227,042
Notes payable and bank loans, long-term portion convertible note	550,000
Convertible Notes Payable - May 2017 [Member]
Short-term Debt [Line Items]
Original issue discount	11,000
Warrants	27,595
Embedded conversion feature	38,595
Convertible note	33,810
Notes payable and bank loans, long-term portion convertible note	111,000
Convertible Notes Payable - July 2017 [Member]
Short-term Debt [Line Items]
Original issue discount	3,000
Embedded conversion feature	58,154
Financing cost	(8,154)
Convertible note
Notes payable and bank loans, long-term portion convertible note	53,000
Convertible Notes Payable - September 2017 [Member]
Short-term Debt [Line Items]
Original issue discount	3,000
Embedded conversion feature	38,338
Financing cost	(6,338)
Convertible note
Notes payable and bank loans, long-term portion convertible note	35,000
Convertible Notes Payable Two - September 2017 [Member]
Short-term Debt [Line Items]
Original issue discount	7,500
Embedded conversion feature	65,332
Financing cost	(17,832)
Convertible note
Notes payable and bank loans, long-term portion convertible note	$ 55,000

Convertible Notes Payable (De45

Convertible Notes Payable (Details Textual) - USD ($)	Sep. 11, 2017	Sep. 07, 2017	Aug. 08, 2017	Jul. 10, 2017	Jul. 07, 2016	May 22, 2017	Feb. 28, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Notes Payable Including Convertible Notes (Textual)
Convertible secured promissory note face value								$ 854,000		$ 854,000		$ 600,000
Net proceeds from issuance of convertible notes										229,500	$ 475,000
Original issue discount								19,226		19,226		0
Financing cost								32,324		32,324
Repayment of notes payable and bank loans										(34,362)	(84,980)
Unamortized discount								157,612		157,612		114,332
Loss on extinguishment of debt								(290,581)		$ (290,581)
HLYK [Member]
Notes Payable Including Convertible Notes (Textual)
Convertible secured promissory note face value												600,000
Convertible secured promissory note maturity date										Jan. 22, 2018
Convertible secured promissory note maturity date, description										The Company expects to repay its outstanding convertible notes of which $111,000 face value matures on January 22, 2018, $53,000 on April 15, 2018, $35,000 on June 15, 2018, $550,000 on July 7, 2018, and $50,000 on July 11, 2018, and $55,000 on September 11, 2018 from outside funding sources, including but not limited to amounts available upon the exercise of the put rights granted to the Company under the Investment Agreement, sales of equity, loans from related parties and others or through the conversion of the notes into equity.
Net proceeds from issuance of convertible notes												475,000
$550k Note [Member]
Notes Payable Including Convertible Notes (Textual)
Percentage of fixed convertible secured promissory note					6.00%
Convertible secured promissory note face value					$ 550,000			550,000		$ 550,000		550,000
Convertible secured promissory note maturity date					Apr. 11, 2017
Warrant to purchase of common stock exercise price					$ 0.09
Net proceeds from issuance of convertible notes					$ 500,000
Original issue discount					$ 50,000
Risk-free interest rate					0.97%
Expected life					5 years
Volatility					40.00%
Expected dividend yield					0.00%
Allocated to warrants					$ 111,479
Convertible note					$ 388,521
Note convertible into common shares										6,875,000
Interest expense								8,318	7,685	$ 24,682	7,685
Warrant terms					5 years
Warrant to purchase of common stock, shares					6,111,111
Fair value of warrants calculated using Black-Scholes pricing model					$ 157,812
Embedded conversion feature					$ 161,479
Note holder fixed price per share					$ 0.08
Unamortized discount								0		0		96,631
$550k Note [Member] | Warrant [Member]
Notes Payable Including Convertible Notes (Textual)
Convertible secured promissory note maturity date							Jul. 7, 2017
Convertible secured promissory note maturity date, description							The holder of the $550k Note agreed to extend the maturity date until July 7, 2017.
Warrant to purchase of common stock exercise price							$ 0.15
Risk-free interest rate							1.89%
Expected life							5 years
Volatility							40.00%
Expected dividend yield							0.00%
Warrant terms							5 years
Warrant to purchase of common stock, shares							500,000
Fair value of warrants calculated using Black-Scholes pricing model							$ 7,506
$550k Note [Member] | Warrant [Member] | HLYK [Member]
Notes Payable Including Convertible Notes (Textual)
Convertible secured promissory note maturity date, description			The holder of the $550k Note agreed to (i) further extend the maturity date of the $550k Note until July 7, 2018, and (ii) further extend the maturity date of the $50k Note (as defined herein) until July 11, 2018.
Warrant to purchase of common stock exercise price			$ 0.30
Risk-free interest rate			1.81%
Expected life			5 years
Volatility			190.86%
Expected dividend yield			0.00%
Warrant terms			5 years
Warrant to purchase of common stock, shares			1,000,000
Fair value of warrants calculated using Black-Scholes pricing model			$ 290,581
Loss on extinguishment of debt			$ 290,581
$50k Note [Member]
Notes Payable Including Convertible Notes (Textual)
Percentage of fixed convertible secured promissory note					10.00%
Convertible secured promissory note face value								50,000		$ 50,000		50,000
Convertible secured promissory note maturity date					Jul. 11, 2017
Common stock fixed price per share					$ 0.10
Convertible note					$ 50,000
Note convertible into common shares										500,000
Interest expense								1,260	1,164	$ 3,740	1,164
Unamortized discount												17,701
$111k Note [Member]
Notes Payable Including Convertible Notes (Textual)
Percentage of fixed convertible secured promissory note						10.00%
Convertible secured promissory note face value						$ 111,000		111,000		$ 111,000
Warrant to purchase of common stock exercise price						$ 0.75
Net proceeds from issuance of convertible notes						$ 100,000
Original issue discount						$ 11,000
Risk-free interest rate						1.80%
Expected life						5 years
Volatility						40.00%
Expected dividend yield						0.00%
Allocated to warrants						$ 27,595
Convertible note						$ 72,405
Note convertible into common shares										317,143
Interest expense								4,168		$ 5,935
Warrant terms						5 years
Warrant to purchase of common stock, shares						133,333
Fair value of warrants calculated using Black-Scholes pricing model						$ 42,305
Embedded conversion feature						$ 38,595
Note holder fixed price per share						$ 0.35
Unamortized discount								35,917		35,917
$53k Note - July 2017 [Member]
Notes Payable Including Convertible Notes (Textual)
Percentage of fixed convertible secured promissory note				10.00%
Convertible secured promissory note face value				$ 53,000				53,000		$ 53,000
Net proceeds from issuance of convertible notes				$ 50,000
Risk-free interest rate				1.23%
Expected life				9 months 3 days
Volatility				183.60%
Expected dividend yield				0.00%
Financing cost				$ 58,154
Note convertible into common shares										362,022
Convertible note conversion features, Description				The $53k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the $53k Note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term				The $53k Note has an interest rate of 10% and a default interest rate of 22%.
Interest expense								1,191	1,191	$ 1,191	1,191
Fair value of warrants calculated using Black-Scholes pricing model				$ 58,154
Net charge on embedded conversion feature				$ 8,154
Convertible into common shares, basis										Based on a 39% discount to the last sale price of the Company’s common stock of $0.24 on September 30, 2017.
Unamortized discount								$ 37,423		$ 37,423
$35k Note - September 2017 [Member]
Notes Payable Including Convertible Notes (Textual)
Percentage of fixed convertible secured promissory note								10.00%		10.00%
Convertible secured promissory note face value		$ 35,000						$ 35,000		$ 35,000
Net proceeds from issuance of convertible notes		$ 32,000
Original issue discount								3,000		$ 3,000
Risk-free interest rate		1.21%
Expected life		9 months 7 days
Volatility		177.20%
Expected dividend yield		0.00%
Financing cost		$ 38,338
Note convertible into common shares										239,071
Convertible note conversion features, Description		The $35k Note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the $35k Note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the $35k Note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Convertible note interest rate term		The $35k Note has an interest rate of 10% and a default interest rate of 20%.
Interest expense								220	220	$ 220	220
Fair value of warrants calculated using Black-Scholes pricing model		$ 38,338
Net charge on embedded conversion feature		6,338
Convertible into common shares, basis										Based on a 39% discount to the last sale price of the Company’s common stock of $0.24 on September 30, 2017.
Original issue discount		$ 3,000
Unamortized discount								32,135		$ 32,135
$55k Note - September 2017 [Member]
Notes Payable Including Convertible Notes (Textual)
Convertible secured promissory note face value	$ 55,000							55,000		$ 55,000
Net proceeds from issuance of convertible notes	$ 47,500
Risk-free interest rate	1.24%
Expected life	1 year
Volatility	175.10%
Expected dividend yield	0.00%
Financing cost	$ 65,332
Note convertible into common shares										381,944
Convertible note conversion features, Description	The $55k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 60% multiplied by the lowest one (1) trading price for the Common Stock during the twenty (20) trading day period ending on the last complete trading day prior to the date of conversion. If, at any time while the $55k Note is outstanding, the conversion price pursuant to this formula is equal to or lower than $0.10, then an additional ten percent (10%) discount shall be factored into the conversion price until the $55k Note is no longer outstanding. In the event that shares of the Company's Common Stock are not deliverable via DWAC following the conversion of any amount hereunder, an additional ten percent (10%) discount shall be factored into the Variable Conversion Price until the Note is no longer outstanding.
Convertible note interest rate term	The 55k Note has an interest rate of 10% and a default interest rate of 12%.
Interest expense								286	$ 286	$ 286	$ 286
Fair value of warrants calculated using Black-Scholes pricing model	$ 65,332
Net charge on embedded conversion feature	17,832
Convertible into common shares, basis										Based on a 40% discount to the last sale price of the Company’s common stock of $0.24 on September 30, 2017.
Original issue discount	$ 7,500
Unamortized discount								$ 52,137		$ 52,137

Derivative Financial Instrume46

Derivative Financial Instruments (Details)	9 Months Ended
	Sep. 30, 2017USD ($)
Debt Instrument [Line Items]
Balance of fair value	$ 161,824
Change in fair value of Derivative Financial Instruments	(5,412)
Balance of fair value	156,412
$53k Note ECF [Member]
Debt Instrument [Line Items]
Balance of fair value	58,154
Change in fair value of Derivative Financial Instruments	(4,769)
Balance of fair value	53,385
$35k Note ECF [Member]
Debt Instrument [Line Items]
Balance of fair value	38,338
Change in fair value of Derivative Financial Instruments	(578)
Balance of fair value	37,760
$55k Note ECF [Member]
Debt Instrument [Line Items]
Balance of fair value	65,332
Change in fair value of Derivative Financial Instruments	(65)
Balance of fair value	$ 65,267

Derivative Financial Instrume47

Derivative Financial Instruments (Details Textual)	9 Months Ended
	Sep. 30, 2017$ / shares
Derivative Financial Instruments (Textual)
Dividend yield	$ 0
Minimum [Member]
Derivative Financial Instruments (Textual)
Risk free interest rate	1.21%
Expected life	6 months 14 days
Volatility	175.10%
Maximum [Member]
Derivative Financial Instruments (Textual)
Risk free interest rate	1.31%
Expected life	1 year
Volatility	183.60%

Shareholders' Deficit (Details)

Shareholders' Deficit (Details) - Stock Warrants [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of the period | shares	10,576,389
Granted during the period | shares	8,990,000
Exercised during the period | shares
Terminated during the period | shares
Outstanding at end of the period | shares	19,566,389
Exercisable at end of the period | shares	19,566,389
Weighted Average Exercise Price, Outstanding at beginning of the period | $ / shares	$ 0.08
Weighted Average Exercise Price, Granted during the period | $ / shares	0.40
Weighted Average Exercise Price, Exercised during the period | $ / shares
Weighted Average Exercise Price, Terminated during the period | $ / shares
Weighted Average Exercise Price, Outstanding at end of the period | $ / shares	0.23
Weighted Average Exercise Price, Exercisable at end of the period | $ / shares	$ 0.23

Shareholders' Deficit (Details

Shareholders' Deficit (Details 1) - Warrant [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding | shares	18,076,389
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.22
Warrants/Options Exercisable, Number Exercisable | shares	8,388,889
0.05 to 0.09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding | shares	8,388,889
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	4 years 7 months 6 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.08
Warrants/Options Exercisable, Number Exercisable | shares	8,388,889
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.08
0.10 to 0.15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding | shares	2,687,500
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	3 years 10 months 25 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.11
Warrants/Options Exercisable, Number Exercisable | shares	2,687,500
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.11
0.25 to 0.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding | shares	7,300,000
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	4 years 6 months
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.33
Warrants/Options Exercisable, Number Exercisable | shares	7,300,000
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.33
0.51 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding | shares	1,190,000
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	4 years 6 months
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.97
Warrants/Options Exercisable, Number Exercisable | shares	1,190,000
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.97
0.05 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding | shares	19,566,389
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	4 years 6 months
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.23
Warrants/Options Exercisable, Number Exercisable | shares	19,566,389
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.23
Maximum [Member] | 0.05 to 0.09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.09
Maximum [Member] | 0.10 to 0.15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.15
Maximum [Member] | 0.25 to 0.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.50
Maximum [Member] | 0.51 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	1
Maximum [Member] | 0.05 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	1
Minimum [Member] | 0.05 to 0.09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.05
Minimum [Member] | 0.10 to 0.15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.10
Minimum [Member] | 0.25 to 0.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.25
Minimum [Member] | 0.51 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.51
Minimum [Member] | 0.05 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.05

Shareholders' Deficit (Detail50

Shareholders' Deficit (Details 2) - EIP [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of the period	1,552,500
Granted during the period
Terminated during the period	(228,750)
Outstanding at end of the period	1,323,750
Shares vested at period-end	795,000
Weighted average grant date fair value of shares granted during the period | $ / shares
Aggregate grant date fair value of shares granted during the period
Shares available for grant pursuant to EIP at period-end	11,829,934

Shareholders' Deficit (Detail51

Shareholders' Deficit (Details 3) - EIP [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at January 1, 2017 | shares	940,000
Granted | shares
Vested | shares	(182,500)
Forfeited | shares	(228,750)
Nonvested at September 30, 2017 | shares	528,750
Weighted Average Grant Date Fair Value, Non-vested at January 1, 2017 | $ / shares	$ 0.04
Weighted Average Grant Date Fair Value, Granted | $ / shares
Weighted Average Grant Date Fair Value, Vested | $ / shares	0.04
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	0.04
Weighted Average Grant Date Fair Value, Non-vested at September 30, 2017 | $ / shares	$ 0.04

Shareholders' Deficit (Detail52

Shareholders' Deficit (Details 4) - Employee Stock Options [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of the period	2,349,996
Granted during the period
Exercised during the period
Terminated during the period
Outstanding at end of the period	2,349,996
Weighted Average Exercise Price, Outstanding at beginning of the period | $ / shares	$ 0.12
Weighted Average Exercise Price, Granted during the period | $ / shares
Weighted Average Exercise Price, Exercised during the period | $ / shares
Weighted Average Exercise Price, Terminated during the period | $ / shares
Weighted Average Exercise Price, Outstanding at end of the period | $ / shares	$ 0.12
Options exercisable at period-end	462,500
Weighted average remaining life (in years)	8 years 10 months 25 days
Weighted average grant date fair value of options granted during the period | $ / shares
Options available for grant at period-end	11,829,934

Shareholders' Deficit (Detail53

Shareholders' Deficit (Details 5) - Stock options [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding | shares	2,349,996
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	8 years 10 months 25 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.12
Warrants/Options Exercisable, Number Exercisable | shares	100,000
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.08
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	0.20
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	0.08
Exercise Prices 0.08 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	$ 0.08
Warrants/Options Outstanding, Number Outstanding | shares	1,600,000
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	8 years 9 months 18 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.08
Warrants/Options Exercisable, Number Exercisable | shares	100,000
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.08
Exercise Prices 0.20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	$ 0.20
Warrants/Options Outstanding, Number Outstanding | shares	749,996
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	9 years 2 months 12 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.20
Warrants/Options Exercisable, Number Exercisable | shares
Warrants/Options Exercisable, Weighted Average Exercise Price

Shareholders' Deficit (Detail54

Shareholders' Deficit (Details 6) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at January 1, 2017 | shares	2,249,996
Granted | shares
Vested | shares	(362,500)
Forfeited | shares
Nonvested at September 30, 2017 | shares	1,887,496
Weighted Average Grant Date Fair Value, Non-vested at January 1, 2017 | $ / shares	$ 0.03
Weighted Average Grant Date Fair Value, Granted | $ / shares
Weighted Average Grant Date Fair Value, Vested | $ / shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Weighted Average Grant Date Fair Value, Non-vested at September 30, 2017 | $ / shares	$ 0.03

Shareholders' Deficit (Detail55

Shareholders' Deficit (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 31, 2017USD ($)shares	Sep. 30, 2017USD ($)Investor$ / sharesshares	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)Investor$ / sharesshares	Sep. 30, 2016USD ($)	Dec. 31, 2016shares
Shareholders' Deficit (Textual)
Fair value of warrant				$ 73,696
Warrant [Member]
Shareholders' Deficit (Textual)
Issued warrants | shares				8,990,000
Risk-free interest rate, Minimum				1.74%
Risk-free interest rate, Maximum				1.95%
Expected life (in years)				5 years
Expected dividend yield				$ 0
Aggregate grant date fair value of warrants issued				$ 496,132
Warrant [Member] | Minimum [Member]
Shareholders' Deficit (Textual)
Expected volatility rate				40.00%
Warrant [Member] | Maximum [Member]
Shareholders' Deficit (Textual)
Expected volatility rate				190.86%
Employee Stock Option [Member]
Shareholders' Deficit (Textual)
Grants shares of common stock | shares		11,829,934		11,829,934
Shares vested at period-end | shares				362,500
Stock based compensation recognized for grants		$ 2,235	$ 2,396	$ 7,504	$ 2,396
Employee Equity Incentive Plan [Member]
Shareholders' Deficit (Textual)
Common stock issued for services, shares | shares				15,503,680
Unrecognized stock compensation		31,655		$ 31,655
Stock based compensation recognized for grants		2,435	$ 3,030	8,215	$ 9,090
Common Stock [Member]
Shareholders' Deficit (Textual)
Sale of common stock	$ 49,996	$ 15,356
Sale of stock, shares | shares	276,850	57,016
Recognized expenses		$ 17,705		$ 46,669
Common stock issued for services, shares | shares				10,313		80,643
Common Stock [Member] | Private Placement [Member]
Shareholders' Deficit (Textual)
Sale of common stock				$ 533,000
Sale of stock, shares | shares				4,412,498
Number of investors | Investor		15		15
Common Stock [Member] | Private Placement [Member] | Minimum [Member]
Shareholders' Deficit (Textual)
Sale of stock, per share | $ / shares		$ 0.10		$ 0.10
Common Stock [Member] | Private Placement [Member] | Maximum [Member]
Shareholders' Deficit (Textual)
Sale of stock, per share | $ / shares		$ 0.30		$ 0.30
Common Stock [Member] | Employee Equity Incentive Plan [Member]
Shareholders' Deficit (Textual)
Grants shares of common stock | shares	207,500

Commitments and Contingencies56

Commitments and Contingencies (Details)	Sep. 30, 2017USD ($)
Commitments and Contingencies [Abstract]
2017 (October to December)	$ 72,227
2,018	281,460
2,019	273,856
2,020	162,055
2,021
Total	$ 789,598

Commitments and Contingencies57

Commitments and Contingencies (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)ft²Segments	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)ft²Segments	Sep. 30, 2016USD ($)
Commitments and Contingencies (Textual)
Operating leases future minimum payments	$ 72,227		$ 72,227
Lease expense, total	$ 77,636	$ 78,940	$ 217,926	$ 266,021
Operating Lease [Member]
Commitments and Contingencies (Textual)
Number of real estate leases | Segments	2		2
Operating Lease [Member] | Naples, Florida [Member]
Commitments and Contingencies (Textual)
Lease beginning date			Aug. 1, 2013
Lease expiration date			Jul. 31, 2020
Area of leasing property | ft²	6,901		6,901
Operating leases future minimum payments	$ 251,287		$ 251,287
Medical Equipment [Member] | Operating Lease [Member]
Commitments and Contingencies (Textual)
Area of leasing property | ft²	361		361
Operating leases future minimum payments	$ 13,140		$ 13,140
MOD [Member]
Commitments and Contingencies (Textual)
Rent paid for office space			2,040
Rent expense related to the marketing agreement	6,120		18,360
Additional amount towards future rent	$ 4,929		$ 4,929
Description of lease agreement			The agreement is effective from January 1, 2017 through July 31, 2018.

Segment Reporting (Details)

Segment Reporting (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Revenue
Patient service revenue, net	$ 480,723	$ 499,448	$ 1,473,639	$ 1,515,293
Operating Expenses
Salaries and benefits	506,206	432,949	1,469,211	1,134,073
General and administrative	480,614	513,404	1,369,018	1,148,564
Depreciation and amortization	6,056	5,718	17,623	15,804
Total Operating Expenses	992,876	952,071	2,855,852	2,298,441
Loss from operations	(512,153)	(452,623)	(1,382,213)	(783,148)
Other Segment Information
Interest expense	27,124	13,409	64,921	24,391
Loss on extinguishment of debt	(290,581)		(290,581)
Financing cost	32,324		32,324
Amortization of original issue discount and debt discount on convertible notes	63,552	100,187	194,120	100,187
Proceeds from settlement of lawsuit		38,236		38,236
Change in fair value of derivative financial instruments	5,412		5,412
Identifiable assets	368,882		368,882		$ 329,511
NWC [Member]
Revenue
Patient service revenue, net	480,723	499,448	1,473,639	1,515,293
Operating Expenses
Salaries and benefits	345,895	347,242	1,025,333	1,001,838
General and administrative	228,278	273,416	619,112	825,603
Depreciation and amortization	5,601	5,718	16,858	15,804
Total Operating Expenses	579,774	626,376	1,661,303	1,843,245
Loss from operations	(99,051)	(126,928)	(187,664)	(327,952)
Other Segment Information
Interest expense	5,723	4,442	17,086	15,424
Loss on extinguishment of debt
Financing cost
Amortization of original issue discount and debt discount on convertible notes
Proceeds from settlement of lawsuit		38,236		38,236
Change in fair value of derivative financial instruments
Identifiable assets	217,344		217,344		240,115
HLYK [Member]
Revenue
Patient service revenue, net
Operating Expenses
Salaries and benefits	160,311	85,707	443,878	132,235
General and administrative	252,336	239,988	749,906	322,961
Depreciation and amortization	455		765
Total Operating Expenses	413,102	325,695	1,194,549	455,196
Loss from operations	(413,102)	(325,695)	(1,194,549)	(455,196)
Other Segment Information
Interest expense	21,401	8,967	47,835	8,967
Loss on extinguishment of debt	21,401		290,581
Financing cost	32,324		32,324
Amortization of original issue discount and debt discount on convertible notes	63,552	100,187	194,120	100,187
Proceeds from settlement of lawsuit
Change in fair value of derivative financial instruments	5,412		5,412
Identifiable assets	$ 151,538		$ 151,538		$ 89,396

Segment Reporting (Details Text

Segment Reporting (Details Textual)	3 Months Ended	9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2017USD ($)Segments
Segment Reporting (Textual)
Number of reportable segments | Segments		2
HLYK [Member]
Segment Reporting (Textual)
Subscription revenue billed and paid | $	$ 2,377	$ 2,377

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Oct. 05, 2017	Nov. 01, 2017	Oct. 27, 2017	Oct. 23, 2017	Oct. 18, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Subsequent Events (Textual)
Common stock, par value						$ 0.0001		$ 0.0001
Net proceeds of common stock						$ 229,500	$ 475,000
HLYK [Member]
Subsequent Events (Textual)
Net proceeds of common stock								$ 475,000
Subsequent Events [Member]
Subsequent Events (Textual)
Convertible note issued			$ 171,500	$ 53,000
Convertible note interest rate term			The note has an interest rate of 10% and a default interest rate of 22%.	The note has an interest rate of 10% and a default interest rate of 22%.
Convertible note conversion features, Description			The note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 35% discount to the lowest closing bid price during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due.	The note may be converted into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the average of the three (3) lowest closing bid prices during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due.
Sale of common stock	$ 38,000				$ 50,000
Sale of stock, shares	211,111				250,000
Sale of stock, per share	$ 0.18				$ 0.20
Warrant to purchase of common stock exercise price	$ 0.30				$ 0.30
Warrant to purchase of common stock, shares	126,666				166,666
Warrant terms	5 years				5 years
Subsequent Events [Member] | Investor [Member]
Subsequent Events (Textual)
Sale of stock, shares		1,000,000
Sale of stock, per share		$ 0.20
Warrant to purchase of common stock exercise price		$ 0.30
Warrant to purchase of common stock, shares		666,666
Warrant terms		5 years
Common stock, par value		$ 0.0001
Net proceeds of common stock		$ 200,000